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1. Introduction 
 
1.1 Through the ages of herpes simplex virus. 
 
The first  descriptions of lesions that resembled those  caused by herpes simplex virus (HSV), 
have been found on a Sumarian Tablet (third millenium BC) and on the Ebers Papyrus (1500 
BC). Nevertheless, the first time we came across knowledge of HSV was with the ancient 
Greeks, where lesions that seemed to creep and crawl along the skin were described by 
Hippocrates with the term “herpes” (1). Through the centuries, investigators have described this 
pathological skin condition with a variety of terms and meanings up to the 17th and 18th centuries 
when a more rigorous definition of herpes emerged. Bateman described a recurrent HSV 
infection as “a restricted group of localized vesicles with a short, self-limited course” (see (1) 
refs therein). The research has progressed from the simple classification of lesions to a 
description of disease, epidemiology of infection and nowadays to the molecular characterization 
of the virus. For many years, the virus was considered to be a troublesome childhood disease and 
an affliction of a few unfortunate individuals. The experimentation and recognition of the 
aetiological agents started between the 19th and 20th centuries.  
In the first half of the 20s, Gruter conducted several animal experiments that confirmed the 
infectious nature of HSV, showing how the virus could be transmitted serially from rabbit to 
rabbit. It is to him that the virology community attributes the merit for the isolation of HSV. 
It is noteworthy that in the 1930s Andrews and Carmicheal laid the foundation of HSV biology 
by observing that only adults carrying neutralizing antibodies were affected by recurrent 
infections. 
In the first part of the 50s,  there was a big development in herpesvirology with the advent of 
culture protocols allowing  isolation of other members of the human herpesvirus family. During 
the 1970s, genital herpes was recognized as a serious sexually transmitted infection that could 
threaten the life of a fetus if the virus was contracted shortly before or at delivery. The public 
tooks into account the problem when newspaper articles were written on the subject, with sexual 
freedom and increase in incidence of sexually transmitted disease. The awareness grew even 
more with the advent of the first cases of HIV. 
The first antiviral therapy developed at the end of the 70s was vidarabine, that reduced the 
fatality of HSV encephalitis, but the real therapeutic advance was the discovery of acyclovir and 
the demonstration of its mechanism of action by Dr Gertrude Elion (1), who was awarded Nobel 
Prize in Physiology and Medicine in 1988. 
The vaccines against herpesvirus have been of great interest since the early 20th century but their 
history has been uncertain. Two vaccines have been evaluated for prophylaxis and therapy, both 
based on viral glycoproteins and an adjuvant. They gave difficult to interpret results e.g. decrease 
of the incidence of HSV-2 infection in women but not in men, so their efficacy has still to be 
proven. 
The beginning of modern research on HSV can be placed between the 1960s and 1970s. During 
this period the size and complexity of the structure of HSV DNA were discovered, as well as the 
large number of proteins that make up HSV particles. This could be called the golden age of 
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research on HSV where a great amount of information on the function of viral genes and virus-
cell interactions was collected. 
In the last twenty years research focused on the therapeutic potential of HSV besides its 
pathogenic properties. HSV has been taken into account as a promising viral vector to be  used in 
immunoprophylaxis and gene therapy. In particular, there are two potential therapeutic uses for 
HSV: 1) delivery of missing, damaged or modified genes to the CNS and 2) engineering of the 
virus to destroy cancer cells. The latter is the topic of my PhD thesis. 
 
1.2 Herpesviridae  family and its classification 
 
A common feature of the family Herpesviridae is the architecture of the virion. A typical herpes 
virion is composed of: a core containing linear double-stranded DNA, a 100-110nm diameter 
icosadelthaedral capsid, an amorphous and asymmetrical tegument around the capsid, and the 
exterior lipid envelope with surface glycoprotein spikes (2, 3). 
The herpesviruses are highly widespread in nature and several animal species are the natural host 
of at least one herpesvirus. Nine herpesviruses have been isolated from humans and they are 
listed in the table below (Table 1.1). 
 
Table 1.1 - Viruses belonging to the human Herspesviridae family (4). 
Designation Vernacular name Subfamily Genome Size 
(bp) 
Abbreviation 
Human 
herpesvirus 1 
Herpes simplex  
virus 1 
α 152 HHV-1          
(HSV-1) 
Human 
herpesvirus 2 
Herpes simplex  
virus 2 
α 152 HHV-2                
(HSV-2) 
Human 
herpesvirus 3 
Varicella-zoster 
virus 
α 125 HHV-3                             
(VZV) 
Human 
herpesvirus 4 
Epstein-Barr virus γ 172 HHV-4                                  
(EBV) 
Human 
herpesvirus 5 
Cytomegalovirus β 229 HHV-5                                            
(HCMV) 
Human 
herpesvirus 6A 
 β 162 HHV-6A                                
Human 
herpesvirus 6B 
 β 162 HHV-6B 
Human 
herpesvirus 7 
 β 153 HHV-7 
Human 
herpesvirus 8 
Kaposi’s sarcoma 
associated virus 
γ 230 HHV-8                              
(KSHV) 
 
 
The known hepersviruses share four basic biological traits:  
i) Production of a large amount of enzymes engaged in nucleic acid metabolism (e.g. 
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thymidine kinase, thymidylate synthetase, dUTPase), DNA synthesis and possibly, 
processing of proteins. 
ii) Synthesis of viral DNA and assembly of capsids in the nucleus. 
iii) Generation of infectious viral progeny associated with the lysis of the infected cell. 
iv) Latency in the natural hosts with expression of only a small subset of viral genes. 
 
There are three subfamilies of the  Herpesviridae family classified by the Herpesvirus Study 
Group of the International Committee on the Taxonomy of Viruses (ICTV) on the basis of 
biological features. 
Alphaherpesvirinae: viruses in this subfamily share efficient destruction of infected cells in a 
wide variety of hosts, rapid spread in culture, short reproductive cycle, and the ability to start a 
latent state infection primarily but not only in sensory ganglia. In this subfamily are the genera 
Simplex viruses HSV-1, HSV-2, Varicellovirus (VZV, pseudorabis virus and equine herpesvirus 
1), circopithecine hepersvirus 2, and bovine mammillitis virus.  
Betaherpesvirinae: the majority of its members has a restricted host range. The reproductive 
cycle takes a long time, a growth in culture is slow and the nuclei of infected cells become larger 
(cytomegalia). The virus establishes latency in several cells type like secretory glands, 
lymphoreticular cells, kidneys and other tissues. The genera Cytomegalovirus (HCMV) and 
Muromegalovirus (murine cytomegalovirus) belong to this subfamily. 
Gammaherpesvirinae:  all members replicate in lymphoblastoid cells, and some cause lytic 
infections in some types of epithelioid and fibroblastic cells. These viruses are specific for either 
T or B lymphocytes and establish latent infections in lymphoid tissue. The Gammaherpesvirinae  
family contains two genera, Lymhocryptovirus (e.g. EBV) and Rhadinovirus (4). This thesis will 
focus on HSV-1. 
 
1.3  Epidemiology of HSV infection 
 
HSV replicates in many cellular types, including neurons where it carries out a lytic cycle and is 
capable of aggressive spread and tissue destruction. The initial HSV infection requires contact 
between the virus and mucosal surfaces or abraded skin. The two viral serotypes (type 1 or 2) are 
transported in a retrograde manner along the axons of neurons that innervate the portal of entry 
to the cell body’s nuclei in sensory ganglia. In the nuclei they ultimately establish a latent 
infection characterized by persistence of viral DNA in the absence of viral protein synthesis. 
Viral replication occurs in a small number of neurons; the viral genome then remains in a latent 
state for the life of the host. In a large fraction of individuals carrying latent HSV, various stimuli 
(damage to nerve endings, hormonal imbalances or emotional stress) result in re-activation of 
virus replication (5). The virus is then transported in an anterograde flow to mucosal membranes 
at or near the portal of entry into the body, and visible sores become active for transmission to 
uninfected individuals (Fig. 1.1).  
The host immune system condition influences the type of HSV infection. Seronegative 
individuals contract primary infection at their first exposure to HSV-1 (facial) or HSV-2 
(genital). This is different from an “initial infection” where a person with antibodies against 
HSV-1 contracts  HSV-2 or vice versa. The clinical manifestations caused by the two serotypes 
are similar although they are usually transmitted by different routes and localize at different areas 
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of the body. These viruses have worldwide distribution with different impacts depending on the 
socio-economic situation of the individuals concerned, no seasonal changes and naturally infect 
only humans. HSV infection is seldom fatal, except for newborns, particularly in the pre-
acyclovir era.  
The incubation period of HSV-1 or HSV-2 is about 4 days and ranges from 2 to 12 days.  
The diagnostic assessment is based on virus isolation in cell culture and PCR detection of viral 
DNA. Symptomatic oropharyngeal disease by HSV-1 is characterized by sores of the buccal and 
gingival mucosa (lasting 2-3 weeks) and by fever between 38 to 40°C. Intraoral ulceration 
lesions indicate primary infection whereas lip lesions suggest recurrent infection. 
Primary genital herpes by HSV-2 appears as macules and papules, followed by vesicles, pustules 
and ulcers. During pregnancy the infection is rarely transmitted to the fetus (5% in utero), infact 
the most transmissions occur during vaginal delivery (80%) or after birth. The infected babies 
frequently die owing to encephalitis and disseminated infection. To prevent mother-to-baby 
transmission, caesarian section is applied. 
Complications in men are rare; aseptic meningitis and urinary retention are more common in 
women. Non primary initial genital infection cause milder symptoms than primary infection 
(fewer lesions, less pain and less like hood of complications). 
Immunocompromised patients are at increased risk of severe HSV infection, they can develop 
progressive disease involving respiratory tract, esophagus or gastrointestinal tract (5, 6). The 
cure for initial or recurrent HSV infection is the topical, oral or intravenous administration of 
acyclovir, a purine-nucleoside analogue prodrug. It is activated by viral thymidine kinase and 
when it is incorporated into viral DNA, it acts as a chain terminator. This treatment keeps 
symptoms under control symptoms and has been successfully employed to treat other HSV 
infection such as encephalitis, hepatitis, pulmonary infection, proctitis or eye infection (6). 
 
 
 
 
Figure 1.1 - Progression of HSV-1 infection in vivo. HSV-1 primary infection occurs in the mucosa of the lips or eye. Here, 
virus replicates actively in cells and enters in the sensory neurons near the portal of entry. The virus then is transported to the 
nerve cell bodies in the trigeminal ganglia. During latent phase the viral gene expression is turned off in ganglia, except for LAT 
gene. Periodically, various stimuli cause virus reactivation. In this phase virions travel in anterograde manner through the axons 
of neurons  toward the primary site of infection (7). 
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1.4  Herpes simplex virus 1 
 
The first human herpes virus discovered was HSV-1 and it is considered the prototype virus in 
the family, and is still one of the most investigated herpes viruses (8). The biological properties 
which make it an interesting research subject are that a) it remains latent in the human host for 
life, b) it reactivates causing lesions and c) it causes several infections. This virus is used as tool 
and model to study translocation of proteins, synaptic connections in the nervous system, 
membrane structure, gene regulation, gene therapy, cancer therapy and many other biological 
problems (9). 
 
 
1.4.1 Virion Structure overview 
 
As mentioned earlier in the text the HSV virion consists of four elements (6, 9): a core, an 
icosadeltahedral capsid surrounding the core, a tegument surrounding the capsid, and an 
envelope.  
A study conducted with cryo-electron tomography on HSV-1 described the virion structure in 
great detail (Fig 1.2) (10). The virion consist of  a pleiomorfic membrane-bound particle. It is 
generally spheric in shape, although some moved away from sphericity which appears to be a 
genuine feature. The bilayer membrane was seen as a continuous smoothly curved surface (5 mm 
thick). Its diameter rangs from 170 to 200 nm, averaging 186 nm and an array of spikes protrude 
from each virion, making the full diameter on average, ~ 200 nm. 
The core contains densely coiled and complex DNA,  with spermidine and spermine proteins that 
neutralize the DNA’s negative charges, conferring a toroidal shape (9). 
The capsid consists of 162 capsomers arranged in a T=16 icosahedral symmetry and an 
intermediate layer organized in a T=4 lattice. The outer and the intermediate layers are organized 
so that channels along their icosahedral twofold axes coincide, forming a direct pathway and 
potential channel between the DNA layer and the exterior of the virion (11). The non-central 
location of the capsid inside the virion allows for proximal pole identification where the capsid is 
near the envelope and distal pole where it is not.. The tegument occupies about two-thirds of the 
volume enclosed within the membrane and at 7 nm of resolution it appears to consist of a 
reticulum of particulate density. Some tegument components appear polymeric; some cellular 
filaments resembling actin were incorporated (10).  
The process which HSV acquires its lipid envelope has given rise to disputes. Some studies 
suggested that virion lipids are similar to those of cytoplasmic membranes and different from 
those of nuclear membranes of uninfected cells (12). The envelope acquisition and the 
subsequent viral egress have been proposed to follow different mechanisms (9 ):  
a) single nuclear envelopment model: the capsids are enveloped at the inner nuclear 
membrane and exit the perinuclear space by means of perinuclear vesicles which bud 
from the outer nuclear membrane. Vesicles are transported, interact with Golgi apparatus 
and virions are then released to the plasma membrane. 
b) the dual envelopment pathway (de-envelopment-re-envelopment pathway): capsids 
9 
 
acquire a primary envelope at the inner nuclear membrane and lose it through fusion with 
the outer nuclear membrane. The capsid is then released into the cytoplasm. The de-
enveloped capsids acquire tegument in the cytoplasm and undergo a secondary 
envelopment  at other membranes in the cytoplasm including Golgi stacks and 
multivesicular bodies; 
c) single cytoplasmatic envelopment: capsids exit from nucleus through enlarged nuclear 
pores. They acquire the envelope budding into cytoplasmic vesicles and are transported 
to the plasma membrane. 
At present, the single cytoplasmatic envelopment (c) is the most popular model of HSV 
maturation and exit.  
The envelope surface contains numerous spikes. The spikes arrangement is not random, they 
usually are few and scattered at the proximal pole and densely packed around the distal pole. 
This distribution could reflect functional associations such as local clustering of glycoproteins 
destined to serially make contact with different receptors during cell entry (13). At least 15 
different viral transmembrane proteins have been identified in HSV-1 particles (14). 
 
 
 
 
 
Figure 1.2 - Structure of  a HSV1 virion A)  A HSV-1 virion has a diameter of about 200 nm. The viral particle consists of an 
icosahedral capsid, which contains the viral DNA with a genome of 152 kbp. Around the capsid, there is an amorphous tegument, 
which contains viral structural and regulatory proteins and is surrounded by an external envelope containing  glycoproteins (8). 
B-C Virion segmented surface rendering tomogram.  B) Virion outer surface with glycoproteins (yellow) protruding from the 
membrane (blue). C) Virion section. The capsid (light blue), the tegument (orange) and the envelope (blue and yellow). Scale bar, 
100 nm. (10). 
 
 
1.4.2 HSV-1 genome organization  
 
The HSV-1 genome contained in the virion core consists of  linear, double stranded DNA 
wrapped as a toroid or spool (15). In vivo, the HSV-1 genome has been found to exist in at least 
three different states: linear, circular, and concatemeric. In the virion, genomes are linear, but 
within hours after infection, end joining has been found to occur, resulting in ‘‘endless genomes’’ 
that have been interpreted to represent circles (15, 16). Thus, genome circularization has been 
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thought to be a prerequisite for viral DNA replication, although there is no direct proof for 
circular replication intermediates. Some experimental results evidence that genome 
circularization is not a characteristic of a productive infection but instead may take place during 
the establishment of latency (17). 
The entire HSV-1 genome consists of 152,000 bp, with a G+C content of 68%. These numbers  
include only single copies of the a sequence at the ends of the L component and do not take into 
account their variation in size (200 to 500 bp each) and number.  
The HSV-1 genome consists of two unique sequences covalently joined, referred to as UL (long) 
and US (short); each region is flanked by inverted repeats: the repeats of the L component are 
designated ab and bʹaʹ, whereas those of the S component are aʹcʹ and ca. The number of a 
sequence repeats at the L-S junction and at the L terminus is variable and their sequences are 
highly conserved. The HSV genome can then be represented as follows: 
 
aLanb-UL-bʹaʹmcʹ-US-caS 
 
where aL and aS contain direct repeats (18). In the viral genome three origins of replication are 
present: oriL located in UL, and two copies of oriS located in the flanking region of US. 
Furthermore, the HSV-1 genome undergoes inversions that result from recombination events 
mediated by the viral DNA replication machinery. These events generate four genomic isomers 
with L and S sequences inverted relative to one another (prototype) in equimolar amounts (9, 
17).  
Herpes simplex virus DNA contains about 90 unique transcriptional units, at least 84 encode 
proteins, several stable non coding RNAs and miRNAs (19). Each viral transcript encodes a 
single protein except for the single transcript of ORF P that also serves as the template for the 
ORF O protein; UL26 which encodes for a transcript cleaved into two proteins, and the mRNA of 
UL3 which contains the ORF of UL1,2 and 3. Many clusters of transcriptional units are 3ʹ co-
terminal (arranged either head-to head, head-to-tail, or tail-to-tail), several examples exist of 
transcriptional units wholly embedded in the coding sequence contained in the larger transcript, 
some of the expressed ORFs are antisense to each other and several transcripts appear not to 
encode proteins. Those best known are the latency associated transcripts (LAT)(9). 
 
 
 
1.4.3 Functional organization of HSV genome  
 
HSV-1 genes fall into at least three kinetic classes, expressed sequentially in a coordinated 
fashion: α or immediate early; β or early and γ or late. The α genes map near the termini of the L 
and S components and are expressed very soon after infection, approximately from 2 to 4 hours 
post infection. The expression of α genes does not require prior protein synthesis. The viral 
tegument protein VP16 promotes their transcription interacting in the nucleus with host cell 
octamer binding protein 1 (Oct1) and host cell factor (HCF1) at the GnTAATGArTTC response 
element in the promoters of α genes. Moreover the transcription initiation of α genes requires the 
demethylation of histones by lysine specific demethylase 1 (LSD1) that belongs to the dynamic 
repressor complex CoREST/REST. The protein is recruited by the VP16/Oct1/HCF1 complex 
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(20). The α genes encode of six proteins designated as  infected cell protein (ICP) ICP0, ICP4, 
ICP22, ICP27, ICP47 and US1.5. Their task is to silence the cellular machinery by inhibiting 
transcription, immune response e.g. block of interferon pathway, RNA splicing, RNA transport 
out of the nucleus and protein synthesis. Some of them also act by promoting the transcription of 
β and γ genes.  This process facilitates the transition from cellular to viral gene expression. With 
few exceptions β and γ genes are distributed in the unique sequences of both the L and S 
components. The exceptions are the ICP34.5 and ORF P genes located in the repeated sequences 
flanking the L component. The expression of the β genes takes place from 4 to 8 hours post 
infection and requires at least the presence of functional ICP4. This protein acts as a repressor 
and as a transactivator involved in replication of the viral DNA and nucleotide metabolism. The 
β genes are UL30, UL42, UL29, UL9, UL5, UL8 and UL52.  Among β genes, two subgroups have 
been identified: β1 genes are expressed within a short time after, or concomitantly with ICP8 
(UL29 single strand binding protein) and ICP6 (UL39 the large subunit of ribonucleotide 
reductase) protein synthesis. The β2 genes are expressed later after α protein synthesis. When the 
β proteins are expressed, most of them localize into the nucleus and assemble onto the parental 
viral DNA molecules in structures called prereplicative sites located near ND10 structures. These 
structures attract a variety of histones, histone-modifying enzymes, coactivators and 
corepressors. The ND10 bodies are dynamic structures consisting of a large number of proteins 
(20).  
The γ genes expression occurs after the onset of viral DNA synthesis. They are subgrouped into 
γ1 and γ2 genes. Neither β2 nor γ1 genes require viral DNA synthesis for their expression. They 
differ because inhibitors of DNA synthesis reduce γ1 but not β2 gene expression. The products 
include structural proteins of mature virions and tegument components required to prepare newly 
infected cells for an efficient infection. γ1 genes (ICP5, glycoproteins gB, gD and ICP34.5) are 
expressed early in infection and are stimulated by viral DNA synthesis whereas the γ2 genes are 
expressed late in infection and are not expressed in the presence of effective concentrations of 
viral DNA synthesis inhibitors.  
 
 
1.4.4 Overview of viral replication  
 
HSV can follow two alternative pathways to enter cells. One is binding to cell membrane 
receptors, followed by fusion at the plasma membrane, the other involves endocytosis of the 
enveloped capsid and receptor-dependent fusion of the enveloped virus with the membranes of 
the endocytic vesicle (21, 22). The fusion of the virus to the cell membrane or to the endocytic 
vesicle causes the release of the virion into the cytoplasm. The capsid and some of the tegument 
proteins are transported to the nuclear pore. The interaction of pore components with the capsid-
tegument structure results in the release of viral DNA into the nucleus. In this compartment the 
transcription of the viral genome takes place as well as its replication and new capsid assembly. 
The viral DNA is transcribed by a host RNA polymerase with the participation of viral factors in 
all stages of infection. 
The synthesis of viral gene products are tightly regulated as already described above. Assembly 
occurs in several stages. After the γ capsid protein synthesis , the capsid assembly occurs in the 
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infected cell nucleus. At the initial stages, some capsid proteins are located in the cytoplasm. In 
particular the major capsid protein VP5, VP26 and VP23 are not able to localize to the nucleus 
without the help of pre VP22 scaffolding proteins and VP19C. When the complex enters the 
nucleus, the capsid proteins are added as hexons and pentons to form a partial capsid together 
with scaffolding proteins. Empty shells containing an internal scaffolding are assembled first and 
the scaffolding is lost in DNA encapsidation. In particular the encapsidation is a process that 
requires HSV DNA concatemer cleavage  into monomers and their packaging.  The viral DNA 
has signals for cleavage and packaging in the α sequences, named pac1 and pac2. The process is 
not well defined but the insertion of viral DNA is concomitant to the displacement of scaffolding 
proteins like VP22a. The assembled capsid can then proceed to the egress from the cell. 
 
 
1.4.5 Latency  
 
When HSV virions enter the nucleus, they can either start lytic replication or enter the latent 
state. This is a particularly successful form of accommodation with the host. Latently infected 
neuronal cells stay alive, and HSV-1 latency sometimes lasts the lifetime of the host. In the latent 
state the viral DNA is circular in shape, bound to histones, and maintained in a repressed state 
with the exception of the latency-associated transcripts (LATs) and a set of microRNAs 
(miRNAs) derived from LAT or its precursor RNA (20). In a fraction of neurons harbouring 
latent HSV, the virus can be reactivated; assembled virion move anterogradely near the initially 
infected site (9). During the establishment of latency, VP16 /HCF1 complex is not translocated to 
the nucleus, and the transcription of α viral genes is prevented.  At the beginning the LAT 
promoter and 5’ LAT exon are associated with acetylated histones, markers of active chromatin 
whereas the lytic gene promoters are not associated with acetylated histone H3 (9). The LAT 
gene localization is within the inverted repeat component that encloses the unique long segment. 
Its product is an 8.3 kb precursor present at low copy (minor LATs) and, upon splicing, it 
generates a series of stable unpolyadenylated RNAs (major LATs, 2 kb and 1,5 kb in size) that 
accumulate to high levels within the nuclei of latently infected neurons (23). The LAT promoter 
is 3ˈ and antisense to the ICP0 gene, a protein highly involved in a transactivation of several 
viral genes. ICP0 is able to start both viral gene transcription from quiescent genomes in cells in 
culture and viral reactivation from latently infected sensory neurons in vivo (23). This protein 
might thus play a key role in the balance between latency and viral reactivation.  
LATs and miRNAs have a role in the maintenance of latency but not in its onset. No viral 
product expressed from LAT has been identified nor its role in HSV-1 latency.  It has been 
observed that ∆LAT mutant viruses can establish a lytic state, but the yields of virus recovered 
from the ganglia may be reduced relative to those infected with wild type virus; furthermore 
these mutants exhibit increased expression of viral genes (18). The number of neurons in murine 
ganglia infected with a LAT deleted virus is lower than that of ganglia harbouring wild-type 
virus. For these reasons LAT has been proposed to “protect” neurons from apoptosis (24).  
HSV microRNAs derive at least in part from LATs. It is not clear whether miRNAs are 
synthesized from LAT or its precursor or from independent transcription. Their functions seems 
to be related to establishing or maintaining latent infection.  Alternatively they could also play a 
role in the regulation of the synthesis or function of some essential α proteins(20). 
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Several findings show that HDAC-1 or HDAC-2/CoREST/LSD1/REST repressor complex also 
have a role in silencing HSV DNA in neurons. It has been reported that HDAC inhibitors 
increase reactivation of virus in vivo and in vitro and that inhibitors of LSD1 (histone 
demethylase) block viral replication and reactivation from the latent state. The repressor complex 
is required for activation of α genes and to block the expression of β and γ genes; it works in a 
manner that is easily overcome in productive infections but not in infections leading to the 
establishment of the latent state (20).  
 
1.4.6 Entry 
 
HSV is considered as the prototype for the Herpesviridae family. It encodes a multipartite entry 
machinery with essential distinct glycoproteins (gB, gC, gD, gH/gL), each one with a specialized 
activity, whereas smaller enveloped viruses possess only one or two fusion glycoproteins for 
entry and fusion functions. The multistep process of fusion that characterizes HSV entry prevents 
the indiscriminate activation of the fusion apparatus (25). 
HSV enters cells by fusion of the envelope with the plasma membrane or after endocytosis 
through neutral or acidic compartments, insensitive or sensitive to bafilomycin A (BFLA), 
respectively. The entry route of HSV differs from cell to cell.The cell is responsible for choosing 
the entry pathway for the virus, routing  HSV to the appropriate site on the cell membrane. For 
example, HSV virions are routed to cholesterol-rich rafts and a dynamin2 dependent acidic 
compartment by αVβ3-integrin. In general, it has also been reported that cellular factors other 
than the glycoprotein D (gD) receptors may address HSV to acidic endosomes or a neutral 
compartment (26).  
The process of viral entry consists of four steps: attachment, recognition of cellular receptor by a 
viral glycoprotein, triggering of fusion and fusion execution. 
First, the virus interacts with the cell plasma membrane through the binding of gC and gB to 
glycosaminoglycans (GAGs)  moieties of heparan sulfate (HS) or chondroitin sulphate (22, 27, 
28). This non-essential binding enhances HSV infectivity but lacks specificity and likely serves 
to create multiple points of adhesion, tethering and concentrating virions at the cell surface. This 
binding is  reversible, and the detached virus is still infectious (25). In some cellular types it has 
been observed that virions accumulate near cell membrane projections, named filopodia through 
the interaction of gB with HS. From there, virions travel with a  lateral movement along the 
length of filopodia to arrive closer to the cell body. This phenomenon was called viral surfing 
and it has been reported to increase infection efficacy directing the virus to cell membrane 
regions enriched in receptors. After viral attachment, gD binds in an irreversible manner to one 
of its specific receptors. gD is able to bind to at least three alternative receptors: nectin-1, 
herpesvirus entry mediator (HVEM or HveA, herpsevirus entry mediator A) and O-sulphated (3-
O-S) moieties of HS. Many of the receptors are broadly expressed in a wide variety of human 
cell types and tissues (24). It is unknown why HSV binds to alternative receptors. The gD 
affinity to nectin-1 and HVEM is of the same order of magnitude (10-6 M); hence, affinity is not 
a basis for preferential usage (29). Likely this serves to increase the chance of a successful 
infection and spread in the human host. When gD binds to its receptor a protein conformational 
change occurs resulting in the triggering of the fusion process (24).  The gD binding signals the 
receptor-recognition and thus triggers fusion, by recruiting the other three glycoproteins – gB, 
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gH, gL. The trio of gB, gH, gL, executes fusion with the plasma membrane or endocytic vesicle 
of the target cell (Fig. 1.3). The trio appears to constitute the conserved fusion machinery across 
the herpesvirus family with the highest degree of sequence conservation seen in gB (30). The 
complex nature of the entry machinery that has no other example in viruses,  and has made the 
complete understanding of  the fusion triggering mechanism difficult. Due to the number of 
proteins working on the entry pathway a fine communication is necessary among them.  The gH 
and gB proteins have created an intriguing scenario about which of the two proteins could be the 
fusion executor. gH has been considered for a long period as a potential HSV-1 fusogen but 
structural studies on its crystal found no homology with any known fusion proteins (31); the 
structure of gB has already been solved and exhibits a remarkable homology to that of VSV 
fusogen, gG. Considering the structure of the gH-gL complex, it is likely that they may activate 
gB for fusion rather than having a direct role in the mechanism of fusion. Exactly how the two 
glycoprotein cooperate to execute fusion is still unclear (32). 
 
 
 
 
Figure 1.3 - Attachment and entry of herpes simplex into cells.  On the top is the pathway associated with HSV endocytosis. 
Below is the pathway related to HSV-1 fusion at the plasma membrane. Initially HSV binds in an aspecific manner to 
glycosaminoglycans on the cell surface (1). In the second step, gD binds to one of its cellular receptors (2) and after a 
conformational change is able to recruit glycoprotein gB, gH and gL triggering fusion at the plasma membrane (3). The naked 
capsid is transported to the nucleus (4,9). Depending on the cell line the virus can also enter by endocytosis  (5-9).  After 
acidification and maturation of the vesicles, the fusogenic complex may form (5-6) and fusion between the virion envelope and 
the vesicle occurs (7). The naked capsid is then releases into the cytoplasm and is transported to the nucleus (8-9) (30). 
 
1.5  Glycoproteins of HSV-1 involved in attachment and entry  
 
1.5.1 Gycoprotein C 
 
Glycoprotein C (gC) is encoded by the UL44 gene (33). It is a 511aa mucin-type glycoprotein 
heavily N- and O-glycosilated and its gene belongs to the γ class of HSV genes. gC contains a 25 
15 
 
aa signal sequence at the N-terminus, a 453 aa extracellular domain, a 23 aa transmembrane 
anchoring domain and a short 10 aa C-terminal cytoplasmatic tail. gC facilitates the adsorption 
of virions into cells by binding to heparan sulphate’s glycosamminoglycans or to a chondroitin  
sulphate (30). In fact, several observations revealed its importance in virus attachment: first,  gC 
projections are long and slender and they are the most externally exposed structures of the virion 
(34). Second, albeit gC is not essential for virus production in cell cultures, mutant virions 
deleted in gC, unlike the negative mutant gB, are not able to bind to the cells. Furthermore, some 
data showed that monoclonal antibodies for gB, gD, and gH inhibited HSV-1 penetration but had 
little or no effect on attachment.  HSV-1 virions with this glycoprotein deleted are defective in 
penetration but bind to cells normally (27, 34, 35). gC serves multiple accessory functions, it has 
the ability to bind to the C3b component of the complement and is also a major viral antigen 
which elicits a strong humoral and cellular immune response during infection (36). It plays an 
important role in the induction of herpetic eye disease in animal models of herpesvirus keratitis 
(33). 
1.5.2 Glycoprotein D 
 
Glycoprotein D serves as the entry receptor-binding protein and is the main determinant of viral 
tropism (37).  Recently it has been reported that the interaction of gD with its receptors is not 
only required to activate the HSV fusion machinery but, in some cell types, also to target the 
virus to the endocytic pathway (38). The structure of gD has been solved for gD alone, 
encompassing amino acids up to 259, and bound to HVEM  (up to aa 285 of gD) or nectin-1 (up 
to aa 285 of gD) (39-41). gD is a type 1 membrane glycoprotein  369 aa long  after the cleavage 
of the signal sequence of 25 aa (42). Its structure consists of  an ectodomain of 316 aa, a 
transmembrane domain located between aa 317 and 399, and a cytoplasmatic tail. The protein 
has six cysteines that form three disulfide bonds (Cys 66-Cys 189, Cys 106-Cys 202, and Cys 
118-Cys 127) and has three N-linked oligosaccharide attachment sites.  
gD is essential to mediate HSV entry. Its ectodomain is organized in three regions with different 
structural  and functional characteristics: the N-terminal, the core and the C-terminal (Fig. 1.4 
A). The first 20 aa of the N-terminal are disordered, flexible and extended when gD is not bound 
whereas they fold back to form a hairpin when gD is bound to HVEM. This region, that contains 
all residues involved in HVEM receptor binding, pack to the core of the protein which it is 
connected to through a short flexible proline-rich region, encompassing aa 45-54 (25). No 
electron density resulted for residue 1 to 22 in the gD/nectin-1 complex. The first 32 amino acids 
are also involved in binding 3-OS-HS but are dispensable for nectin-1 binding and usage (41, 
43).  
The core includes an Immunoglobulin Variable (IgV) folded region (aa 56 to 184) and a helix 
(-helix 3) of 17 aa that ends at aa 240. In the crystal, helix 3 is positioned between IgV and the 
N-terminus (Fig. 1.4 B,C). Downstream of the helix 3 is a long flexible proline rich region, 
spanning aa 244-312. From studies presented by Zhou and Roizman (37) residues 61–218, 
encompassing almost entirely the Ig core, do not execute a function required for HSV-1 entry 
into cells. Indeed, it was hypothesized that the Ig core can serve as a scaffold, and to connect the 
functional C- and N-terminal regions. This consideration was further confirmed because its 
removal and substitution with a heterologous ligand such as a scFv to HER2 does not impair the 
functionality of the protein (44). 
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The C-terminus of the ectodomain (aa 250/260-310), designated as pro-fusion domain (PFD),  
carries a region required for the trigger of fusion and for the interaction with other viral 
glycoproteins (45). It has a flexible conformation that has made it impossible to determine the 
structure in receptor bound gD whereas in unbound gD it folds back around the core towards the 
N-terminus. The PFD is essential for virus entry, in fact the insertions or deletions in the segment 
250-310 impair infection and cell-cell fusion (25). Furthermore, it has been reported that the 
soluble form of gD, as gD285 and gD306, rescue the infectivity of a gD null virus whereas 
gD260 lacks this ability.  
PFD is also responsible for the “switch-on” mechanism that allows activation of the virion near 
the cell surface. In the receptor free complex, the C-terminal region is in an auto-inhibited 
conformation where PFD folds back around the core stabilized by contacts that include Trp294 
outside of PFD. In particular, amino acids 280 to 306 are located in the position which is 
occupied by the first 20 aa of D in the gD/HVEM complex. This is consistent with the increased 
receptor affinity of the C-terminal truncated form of gD compared to the full length molecule 
(41). The Trp294 side chain is located toward a groove on the gD surface anchoring the PFD in 
proximity of the N-terminal region. The PFD of gD has been supposed to stay  in balance 
between this closed state and a partially open state, with the side chain of Trp294 in and out of 
the groove respectively. The receptor binding may change this equilibrium and lock gD in the 
open conformation. 
gD residues involved in Nectin-1 binding, different from those in HVEM, are not in the same 
confined region but resulted independent and located downstream of residue 32. The recent 
gD/Nectin-1 solved structure definitively indentified the contact region between the two 
molecules and show key residues (Y38, D215, Q132, L220, R222, F223) that make contact with 
the receptor (Fig 1.4 D). In the glycoprotein/receptor surface contact  there are several residues 
that previously have been shown to affect nectin-1 binding when mutagenized (Y38, H39, Q132, 
D215, L220, P221, R222, R223) whereas others have been proposed for the first time. Most of 
the residues identified are in the gD C-terminal  of the ectodomain while Y38 and Q27 are 
located in the N-terminal portion (41).  
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Figure 1.4 - Structure of gD in HSV-1. A) Linear  representation of domains in mature gD. The colors are the same in  panel A, 
B and C. B) Crystal structure of gD ectodomain in a free conformation, HVEM binding site is unstructured. C) Crystal structure 
of gD/HVEM (light blue). The N-terminal region of gD forms a hairpin that contacts the receptor. Critical residues for nectin-
1binding are represented as brown space fill. Q27 and L25 are residues involved in HVEM binding, Ig core in yellow, HVEM 
binding residues in green, residues 185 to 250 from C-terminus of ectodomain in light gray (25) . D) gD surface representation 
located in gD/nectin-1interface. Nectin-1 contact area is colored in blue and magenta. Residues in blue have been shown to 
impair nectin-1 binding while magenta residues have been proposed for the first time (41). 
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1.5.3  Glycoprotein B 
 
Glycoprotein B (gB) is a 904 amino acid trimeric protein encoded by the UL27 gene. gB’s main 
functions are associated with two steps in HSV entry. A non-essential function is attachment of 
the virus to the cellular membrane through the binding to a modified heparan sulphate. The 
second, essential, function is the fusion of the virus with the host membranes. The non specific 
interaction between gB and the cells occurs via a binding site located between aa 68-76 of the 
protein,  whereas the fusion is executed not by gB alone but require in addition of gH and gL. To 
further complicate  herpes entry mechanism it has been demonstrated that gB interacts with its 
own receptors, other than heparan sulfate (46). It has been reported that a soluble form of gB 
binds to cells lacking HS and this inhibits HSV-1 infection in some cell lines (47). To date, three 
possible gB receptors have been identified. Satoh and coworkers demonstrated that the paired 
immunoglobulin like-type 2 receptor (PILRα) interacts with gB mediating HSV-1 infections. 
(48) Furthermore, their experiments showed that anti-PILRα or anti-HVEM  antibody inhibits 
HSV-1 infection of monocytes, which constitutively express both PILRα and HVEM. However, 
interaction between gB and PILRα alone does not mediate membrane fusion in the absence of 
HVEM and gD. So PILRα acts as an essential co-receptor for viral entry (49).  Another receptor 
for gB was identified in myelin-associated glycoprotein (MAG), expressed in neural tissue. 
Indeed, gB is able to cause cell-cell fusion interacting with MAG in the presence of gH /gL (48).  
Recently, an intriguing discovery of a third gB receptor has been made (50). The non muscle 
myosin heavy chain IIA (NMHC-IIA) has been found to interact with gB, functioning as an HSV 
entry receptor. An antibody against NMHC-IIA blocks infection in susceptible cells and 
moreover the knockdown of the putative receptor inhibits the infection in the presence of the 
HSV entry machinery (gB, gD, gH/gL). The protein is normally localized in the cytoplasm 
where it is known to perform its function. During HSV absorption there is a marked enrichment 
of NMHC-IIA at the plasma membrane. 
gB consists of an ectodomain of 696 amino acids, a transmembrane of 69 aa and a cytoplasmatic 
tail of 109 aa (51).  The ectodomain of gB is needed for fusion and some identified mutations 
confer temperature sensitivity entry (52). 
The cytoplasmatic tail carries two alpha helices that negatively regulate the fusogenic process. 
The carboxyl-terminal helix contains two endocytosis domains, named YTQV 889-892 and 
LL871, and one mutation in the aminoterminal confers a syncitial phenotype (R858H, syn 3). 
Deletion  of the two alpha helices blocks gB internalization as demonstrated by the increase of 
fusion assay efficiency and the appearance of a syn phenotype. 
gB is the most conserved entry glycoprotein across the Herpesviridae family and its crystal 
structure shows a surprising similarity with the postfusion conformation of protein G from 
vescicular stomatitis virus (VSV G) ectodomain (53, 54). This similarity suggests  that gB is the 
fusion executor in HSV. Although both proteins do not show a typical fusion peptide they are 
able to trigger the fusion between viral and cellular membranes. 
The crystal structure of gB ectodomain shows that it is a trimer stabilized by several points of 
contact. 10 cysteins residues to create 5 disulfide intramolecular bonds (32). Each subunit of the 
trimer consists of five domain (Fig. 1.5). Domain I, the base, is a continous polypetide chain 
folded like a pleckstrin homology (PH) domain. Generally, this fold serves to proteins  as a 
scaffold mediating cytoplasmatic signaling pathways such as phophoinositide binding. 
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Monoclonal antibodies against this domain are able to block HSV-1 entry (55). Uchida et al. 
found the substitution D285N associated to A549T (domain III) to enhance virus entry. Maybe 
the two mutations hypersensitize gB to respond more promptly to signals from gD therefore the 
authors speculated that this includes the possibility that the mechanism involves a change in the 
yet unknown region of gB-gD contact (56). Domain II, designed as middle, consists of two 
discontinous fragments (142-153 and 364-459) in which a six-strand β barrel similar to a PH 
domain is present.  Domain III, named as core, comprises three discontinuous segments (117-
133, 500-572 and 661-669) and shows a long α helix of 44 residues that form with the other 
protomers essential contacts for the oligomerization. Domain IV is the crown of the molecule 
and does not seem to be related to other known structure. It encompasses two discontinuous 
fragments linked by a disulfide bond. The last domain (V) is the arm and  extends from the 
crown to the bottom of the monomer. The long α helix forms a central coiled coil structure with 
other protomers which is the responsible for the trimer stability (32). 
 
 
 
Figure 1.5 – Crystal structure of HSV-1 gB ectodomain – A) Linear representation of gB domains. B)  On the left: ribbon 
diagram of single domains in one protomer. The five domains are highlighted. On the right: structure of the gB trimer (32). 
 
 
1.5.4 gH/gL complex 
 
The heterodimer gH/gL is highly conserved among Herpesviridae family and both gB and gH/gL 
are required for efficient viral entry and cell fusion in all herpesvirus (31). Numerous 
neutralizing antibodies are directed to gH, stressing its importance in virus infection. The role of 
20 
 
gH in fusion has been confirmed by experiments where neutralizing antibodies to gH block virus 
entry but not the binding to the host cell surface (57). A receptor for this protein has not yet been  
found, but indirect evidence points to the existence of a receptor (26). It was reported that a 
soluble form of gH/gL immobilized on plastic facilitates the adhesion of CHO cells transiently 
overexpressing a number of integrins, in particular, αVβ3 integrin (58).  
gH, encoded by UL22 gene, is a protein of 838 residues with a signal peptide of 18 aa, a  large 
ectodomain of 785 aa, only one transmembrane domain and a short cytoplasmatic domain. gL is 
224 amino acid long and is devoid of a transmembrane region. In the mature virions the two 
proteins are always found in a stable 1:1 complex (31). Recently the three-dimensional crystal 
structure of the complex has been resolved for HSV-2 gH/gL showing a “boot like” conformation 
(Fig. 1.6) (31). gH consists of three domains which are located as continuous segments. Domain 
H1 is placed in the upper part of the boot and is divided in two subdomains (H1 and H2) 
connected by a short linker. This is the only domain that makes contact with gL forming a mixed 
β σheet with four strands coming from gL. Three short helices are also preset in H1 domain.  
Domain H2 is globular consisting mainly of 13 alpha helices and corresponds to the terminal part 
of the boot. It is composed by a β sandwich of 10 strands with five strands for each part.  
Most of gL has not a regular conformation, only 30% of the protein has a secondary structure 
with three helices and two β sheets. The protein contains two disulfide bonds essential for the 
function of the complex and to fold gL in the proper shape. gL activity is needed for the correct 
folding and trafficking of gH, but it cannot be defined as a chaperone protein because it remains 
closely attached to gH also after the folding phase. It is more likely a scaffold that creates with 
gH wide complementary contact surfaces. Thus, it was proposed that gH and gL need each other 
to stabilize their conformation. 
In the past it was proposed that gH/gL exerted the function of a fusogen. On the basis of the 
recent crystal structure of HSV-2 complex, gH/gL do not resemble any known viral fusogen. 
Moreover, the putative fusion peptides inside the structure are buried and involved in sheets. 
Their removal would affect complex stability. So it has been proposed that gB is the real fusogen 
and the complex works as a positive regulator coordinating the transition of gB into its fusion 
active state (31). 
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Figure 1.6 –Structure of gH/gL complex in HSV-2.  A) Linear structure of gH and gL showing domain arrangements: domain 
H1A and H1B (green), domain H2 (yellow), domain H3 (orange), gL (blue).  Unsolved structures are indicated as dashed lines. 
B) Three dimensional side view of gH/gL. Dotted lines show unsolved fragments. Sugars, cysteins and  disulfide bond are 
indicated in grey, yellow spheres and red stick respectively (31).   
 
1.6 Glycoprotein D Receptors 
 
1.6.1 Nectins 
 
Nectins are immunoglobulin (Ig)-like Ca2+ dependent cell adhesion molecules (CAMs) essential 
for several cellular activities like cell-cell adhesion and polarization, differentiation, movement, 
proliferation and survival. The family includes four members (Nectins-1, -2, -3, -4). They are 
expressed in different cell types including epithelial cells, neurons and fibroblats and have two or 
three splicing variants designated with Greek letters (30). Nectins are involved in the creation of 
cell-cell junctions like adherent junctions between neighbouring epithelial cells and fibroblasts 
and in the establishment of apical-basal polarity at cell-cell adhesion sites. They also are implied 
in the formation of tight junctions in epithelial cells. Nectins form homo-cis-dimes, but non 
hetero-cis-dimers. Each protein then forms homo-trans-dimers.  
Nectin1 and Nectin-2 were initially isolated as receptors for α-herpesvirus and were called PRR1 
and PRR2 respectively. All the members, except Nectin-1γ, have an extracellular region with one 
Ig V-like domain, two C-like Ig domains and 8 potential sites for N-Linked oligosaccharides, a 
single transmembrane region, and a cytoplasmatic tail region (59-61). The second Ig-like loop of 
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the protein is involved in the formation of the cis-dimers, whereas the formation of the trans-
dimers needs of the first Ig like loop (59). 
In this region the proteins bind the filamentous (F)-actin binding protein afadin, through its PDZ 
domain, and the cell polarity protein partitioning defective 3 (PAR3) (60). The interaction with 
afadin is not necessary for the formation of the cis dimers or the trans-dimers. The C-terminal 
conserved domain, which is absent from nectin-1β, activates a signalling that involve several 
extracellular and intracellular molecules like Ras, CDC42 and Rac small G proteins (59).  
gD binds physically nectin-1 and crystal structure of gD bound to Nectin-1 have been recently 
solved. The binding site of gD spans from aa 1 to 250 and requires exclusively the β sheets of the 
V domain of nectin-1 (41) (Fig. 1.7). The highest affinity was found for the truncated form of gD 
at residue 250 (30). An important interaction involves Phe 129 of Nectin-1; in the complex this 
residue is inserted in the pocket formed by residue between the α3 helix and the side chain of 
Phe 223 of gD. The mutation of Phe 129 impairs the binding to gD. There are similarities in the 
structures of the nectin-1 dimer and the gD/nectin-1 complex. The crystal structure of the 
complex gD/nectin-1 showed that binding of gD contacts many of the same residues involved in 
nectin-1 dimerization. This finding demonstrates that gD binding impair nectin-1 dimerization 
and thus interferes with nectin-1 mediated cell adhesion. Other non- enveloped adenovirus, 
reovirus and measles interact with a similar regions of their receptors which are also Ig-like cell-
adhesion receptor CAR, JAM-A and SLAM (41).  
 
 
 
Figure 1.7 - Structure of the gD/nectin-1 complex.  A) Linear  representation of human nectin-1 and HSV-1 gD. N-
glycosylation sites are drawn as lollipops. Signals peptides are shown as white boxes and the transmembrane segments as hatched 
boxes.  B) Ribbon representation of the gD/nectin-1 complex. Dotted lines represents unsolved loops (41).  
1.6.2 HVEM   
 
Herpes virus entry mediator A (HVEM, HveA) is a member of the tumor necrosis factor receptor 
superfamily (TNFR) (62). Its members are molecules that transmit signals for the regulation of 
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cell proliferation, differentiation and for apoptosis (30). HVEM is mainly expressed on activated 
T-lymphocytes where it mediates HSV entry , however its distribution may be wider considering 
its presence in several cultured cells line together with nectin-1 (30, 63). The receptor consists of 
an ectodomain with four typical cystein-rich domains (CRD) of ∼40 residues each and a 
cytoplasmic tail with sequences that signals the ligand binding  (Fig. 1.8) (25, 39). In particular 
the cytoplasmatic tail interacts with several members of TRAF family (TNFR-associated factor) 
and leads to the activation of NFκB, Jun N-terminal kinase, and AP-1 (64). HVEM binds directly 
to gD and mediates entry of most HSV-1 and HSV-2 strains (65). HSSV entry and gD binding 
are blocked by a monoclonal antibody that binds CRD1, but biochemical studies showed that 
both CRD1 and CRD2 are necessary and sufficient  for gD binding (66). The gD-HVEM 
interface focalized on the hot spot HVEM-Y23 phenol ring that protrudes into a crevice on the 
surface of gD and site-directed mutagenesis showed that this residue is essential for gD binding 
(39, 65). Mutagenic studies have also showed that several residues in the contact surface 
between gD and HVEM are clustered near an intermolecular antiparallel β-sheet formed by 
HVEM residues 35 to 37. These residues, such as residues in CRD2 contributed to gD binding 
(65).  
 
 
Figure  1.8 - Linear structure of HveA – Black circles identified glycosylation sites where TM indicates the transmembrane 
region (65). 
 
 
Comparison between  gD/HVEM and gD/nectin-1 complex 
The binding site of nectin-1 and HVEM on gD are different. Only the first 32 N-terminal 
residues of gD folded as a hairpin interacts with HVEM and the binding involves hydrogen 
bonds through main and side chain atoms. Indeed, several disperse gD residues, between N-
terminal and C terminal extension of its ectodomain, take contact with the V domain of nectin-1. 
The structural superimposition of the two receptors shows that the most part of amino acids of 
nectin-1 involved in gD binding are deeply hidden by gD-N-terminal residues in the gD/HVEM 
complex. It can be concluded that likely the binding to one receptor interferes with binding of the 
other (41). A soluble form of nectin-1 is able to block virus entry in HVEM expressing cells (67). 
 
 
 
 
1.6.3 3-O-sulfated Heparan sulfate 
 
The third class of HSV-1 receptors are 3-O-sulfated heparan sulfates (3-OS HS). They are a 
modified form of HS created by the enzymatic activity of 3-O sulfotransferases (3-OSTs). This 
type of non proteic receptors are polysaccharides, containing specific sulfated motifs that 
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specifically mediate HSV-1 entry (68). 
Heparan sulphate are expressed in a great variety of cell types (69). Interestingly, although both 
HSV-1 and HSV-2 use HS during the attachment phase in viral entry, HSV-1 can bind to distinct 
modification sites on HS that HSV-2 is unable to, which could explain some of the differences in 
cell tropism exhibited by the two viruses (68). Heparan sulphate chains consist of repeating 
uronic acid (d-glucuronic acid or l-iduronic acid) and d-glucosamine disaccharide units (69).  
 
 
1.7 Viruses as oncolytic agents 
 
Some viruses have an intrinsic cytolytic activity and since their discovery, at the beginning of the 
nineteenth century, they were considered attractive agents against tumors (70). The idea that a 
virus could be employed as a drug to treat cancer disease stemmed from the observation that 
some cancer patients affected by natural viral infections, showed a brief period of clinical 
remission. This was true especially for hematological malignancies like leukemia (71, 72). This 
observation laid the groundwork for the birth of oncolytic virotherapy whose aim is to exploit the 
ability of virus to infect and kill cells in order to obtain the selective elimination of cancer cells. 
The purpose of this strategy is twofold: (i) to limit the growth of the tumor mass and (ii) to treat 
tumors and metastases for which there are no current effective therapies (73). Oncolytic 
virotherapy offers several advantages. First, it is possible to kill selectively only mitotically 
active neoplastic cells through the genetic engineering of viruses. Second, it can make use of 
replication competent viruses to obtain a spread of infection to tumor cells distal from the 
injection site. In this way tumor cells lysis is not confined to the initially targeted cells. Third, 
some viruses can be “armed” to potentiate their oncolytic activity  through the introduction of 
heterologous genes, e.g. boosting the antitumoral immunity with IL-12 cytokine introduction-. 
Lastly  oncolytic virotherapy can be combined with standard clinical therapy (74). From the first 
evidence of a viral antitumor activity, several attempts have been made to use viruses as 
therapeutic agents coupling them with new advances in surgical radiotherapy, chemotherapy, and 
immunotherapy.  
 
1.7.1 Virus retargeting 
 
For viruses with either a natural or partial tropism for the target cancer cells the challenge with 
viral tropism is to introduce mutations that make the virus able to enter and replicate only in 
cancer cells and to preserve its oncolytic activity. The approaches were: virus retargeting to 
specific cancer surface molecules, virus activation by cancer-specific proteases, control of viral 
transcription and replication by tissue-specific promoters and exploitation of cancer cell defects 
(75). 
Some of the viruses belonging to the retargeted class have their surface glycoproteins engineered 
in order to recognize only specific cancer receptors or to be activated by molecules present in the 
cancer environment. In measles virus (MV), the epidermal growth factor (EGF)  or the insulin-
like growth factor 1 (IGF1) were inserted in MV hemaglutinin by Schneider and coworkers and 
the resulting viruses could infect cells expressing EGR and IGF-1 receptor that were not 
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susceptible to infection before (76). Recent years the use of single chain antibodies to retarget 
viruses has been widely applied. These  molecules overcome the problem of the large size of an 
entire antibody tetramer and maintain the specificity for the target cells. Several viruses have 
been engineered to express scFv like anti-EGFRvIII or anti-prostate specific membrane antigen 
(PSMA) for MV (77), anti-vascular endothelial growth factor (VEGF)  for vaccinia virus (78) or 
human epidermal growth factor receptor 2 (HER-2) for HSV (79, 80). 
Another approach was to exploit the fact that nearly all cancer cells express matrix 
metalloproteinases (MMPs) at high levels conferring viral cancer specificity to viruses. MV has 
been engineered to express its fusion protein F with an hexameric sequence recognized by an 
MMP  instead of furin, the natural activator of MV fusion protein. The modified virus was 
rescued and strongly restricted on primary human hepatocytes (75, 81, 82), whereas it was 
unable to infect cells that did not express MMP in the extracellular matrix. 
However, the greatest challenge in retargeting viruses to cancer specific receptors is to 
deprogram the virus from its natural receptor recognition. This result can be achieved either 
through mutagenesis of several residues known to be responsible for the virus receptor binding 
or through retargeted molecules on a virus surface that can mask the normal site of virus 
attachment. 
Another strategy considered here is that in order to control the specificity of viral replication, 
essential gene products can be controlled by cancer specific promoters. DNA viruses are the 
most suitable candidates for this approach because they can tolerate large DNA insertions. In 
adenoviruses, E1A gene that normally transactivates viral promoters to initiate the replication 
cycle has been put under the prostate specific membrane antigen to reach cancer type specificity 
(83). Other adenoviruses have been engineered to be controlled by the survivin promoter, active 
only in cancer cells (84). 
Oncolytic virus design can also exploit some cancer specific defects in order to reduce viral 
toxicity to normal tissue. For example, many o-HSV are deleted in the neurovirulence gene or in 
genes related to nucleotide metabolisms in order to obtain viruses able to replicate only in cancer 
dividing cells (see below in the text). ONYX-015, a derivative of adenovirus type 5 (dl1520 
strain), is a conditionally replicating virus deleted in the E1B gene and it was the first tumor-
selective OV to show antitumor activity in a clinical setting (85, 86). E1B gene interacts directly 
with a cellular p53 blocking apoptosis in infected cells, so its deletion makes the virus able to 
replicate only in cells with a non functional p53 (87). However, ONYX-015 possesses 
insufficient antitumor potency as a single agent because, after intra venous administration, it is 
not able to infect efficiently tumor matastases, exhibits slow replication and spread in solid 
tumors (24). Nowadays it is administered in combination with chemotherapy and the results are 
encouraging in patients with head and neck cancer.  H101, an E1B-55k mutant adenovirus has 
passed successfully a phase III clinical trial in China and has been approved by the Chinese FDA 
for its use in patients with head and neck cancer in combination with chemotherapy (87). 
 
 
1.7.2 Arming viruses 
 
Although the retargeting approach has been proven to be effective in specifically directing 
viruses against cancer cells, other strategies have been evaluated to potentiate viral oncolysis and 
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to increase the clearance of tumor masses through the stimulation of the immune system. The 
arming can be achieved for example (i) through the insertion of transgenes that convert a prodrug 
into a harmful compound, (ii) the insertion of immunomodulatory molecules able to recruit the 
immune system cells, (iii) the introduction of pro-apoptotic transgenes that force the cell to 
commit suicide only at a late stage of infection. 
An example of arming through an immune stimulating protein is the vaccinia virus that has 
recently been used as an armed replication competent oncolytic virus that selectively infects 
tumors. Vaccinia virus is suitable as oncolityc agent because it has evolved mechanisms that 
facilitate intravenous stability and circulation to distant tissues.  JX-594 is an engineered 
vaccinia oncolytic virus with the deletion of viral thymidine kinase gene and expression of 
granulocyte-macrophage colony stimulating factor (GM-CSF) and LacZ. Recently the first phase 
I dose escalation trial of JX-594 with a single intravenous infusion in human metastatic solid 
tumors was reported. The virus has been generally well tolerated (88).  
An example of proapoptotic transgenes is an adenovirus modified to express the TNF-related 
apoptosis inducing ligand (TRAIL). This molecule leads to apoptosis in a wide set of tumor cells 
without dependence on p53 status. The virus was effective both in vitro and in vivo: mice tumor 
models revealed efficient replication of this vector and the elimination of preestablished liver 
metastases (75). 
 
1.7.3 Shielding viruses 
 
The systemic route of administration for the treatment of tumor metastases is still an open issue 
for oncolytic virotherapy. Preexisting immunity against a specific viral agent can preclude its 
spread in the tumor due to its inactivation by the host immune system. To overcome this problem 
some strategies have been designed to permit the co-existence of the OV and the host immunity 
(75). On the other side the injected OV itself can induce a local innate immune response that 
facilitates the elimination of tumor masses. The first preclinical studies are normally conducted 
on immunodeficient mice that do not represent the real state of the final patient.  
The combined use of virotherapy and chemiotherapy can help to limit the action of neutralizing 
antibodies in the blood stream. Cyclophosphamide (CPA) is normally administered as 
chemotherapeutic but at the same time it causes the immune-suppression state of the patient. For 
this reason it was used in combination with different OVs and it has already shown enhanced 
viral delivery and efficacy through a decrease of neutralizing antibodies or depletion of T cells 
(89). In a recent study however, it has been shown that vescicular stomatitis virus (VSV) used in 
combination with CPA caused  a  loss of chemotherapeutic functions, impairing the oncolysis. 
This was likely the result of the viral-induced activation of immune suppressive components 
(90). Another approach to tricking the  immune system lays in the construction of chemical 
shields with polymers such as polyethylene glycol (PEG). The polymer coated virus can get 
around the immune system avoiding the macrophages’ attack and having time to reach the tumor. 
So far adenovirus has been modified in this way and the method has proved satisfactory (91). 
The last strategy for virus shielding is the use of carrier cells that delivery the virus through the 
blood stream to the tumor mass. The cells, chosen as vectors, must have some characteristics: 
they should be highly susceptible to virus infection, not be rapidly lysed by the virus, and spread 
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the infection to the cancer cells (92).  
 
 
1.8 Oncolytic HSV  
 
HSV offers several advantages for cancer therapy as compared to other viral vector systems. In 
addition to its natural neurotropism, (i) HSV has a broad host range that allows it to infect and 
replicate in many cell lines; (ii) a distinct benefit compared to other o-viruses is the availability 
of specific anti HSV therapy for the treatment of undesired infections (Acyclovir, Ganciclovir 
etc.); (iii) it also has a large genome size of about 152 kbp, part of which consists of non 
essential genes that can be replaced with novel mutagenesis technologies (e.g. GalK 
recombineering) of up to 30 kbp. The adenovirus, whose genome any way is five times smaller, 
shares this last characteristic with HSV, whereas the genome of MV and adeno-associated virus 
(AAV)  do not have space to additional genes. Other advantages are that (iv) the viral DNA does 
not integrate into the cellular genome, eliminating the concern of insertional mutagenesis (8, 24, 
73); (v) the glycoproteins of the entry apparatus are well known and tolerate the insertion of 
heterologous ligands and modifications  (80, 93, 94); (vi) clinical trials have highlighted that it is 
possible to construct attenuated, replication competent HSVs that show efficacy in several tumor 
types; (vii) HSV completes its replication cycle in 20 h, in contrast to adenovirus whose 
replication cycle typically lasts 48-72 h (95). Finally,(viii) a good characteristic is HSV’s ability 
to spread cell to cell directly through cell junctions and to disseminate in the extracellular space, 
allowing an efficient viral penetration within solid tumors (24). 
The original pioneering research on HSV as oncolytic viruses was conducted  by Martuza and 
coworkers and  in 1991 they published the first evidence that an oncolytic  mutant HSV-1 
prolonged survival time of nude mice bearing intracranial human glioma (96). The virus had 
been deleted in the thymidine kinase (TK) gene, encoded by UL23. TK cooperates in the 
synthesis of deoxyribonucleotides to facilitate viral DNA replication in non dividing cells and it 
plays a protective role converting non-toxic prodrugs such as ganciclovir and acyclovir into toxic 
metabolites (24, 96 ).  However, it was so neurotoxic at high titers and insensitive to antiherpes 
treatments that its use in clinical trials was stopped (97). However, this constituted the proof of 
principle that the strategy could be followed. Today, with regard to safety, TK genes must be 
maintained to stop undesired infections due to potential HSV mutations (73). 
Further knowledge about cancers and virus biology has allowed the design of OV combining 
different strategies as the modification of viral tropism, the arming of viruses to enhance 
antitumoral immunity or the shielding of viral particles to escape host immunity (Cattaneo 
2008). 
The first and second generation of o-HSV share the attenuation of the virulence and are  
conditionally replicating viruses (single or double mutants) with the deletion of some 
nonessential genes to avoid replication in normal cells. The third generation includes attenuated 
viruses with enhanced antitumor immunity (e.g G47∆ ). Subsequently the third generation 
developments were focused on arming viruses with cytokines like IL-12 and GM-CSF 
incorporated in an attenuated backbone. The last generation includes the tropism retargeted 
viruses whose aim is to enter cells through tumor specific receptors other than their own.  
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Conditionally replicating HSV:  A rapid cellular division is a main characteristic of tumor cells 
and this  implies a large availability of nucleotide precursors for DNA synthesis. In this regard 
early attempts to use o-HSV focused on genes involved in nucleotide metabolism to force 
engineered viruses to replicate only in mitotically active cells (97). So the first conditionally 
replicating virus was a thymidine kinase-negative mutant of HSV-1 (dlsptk) (96). Other viruses 
were developed with mutations in viral enzymes involved in nucleotide metabolism as 
ribonucleotide reductase (RR) and uracil deglycolyase (UNG) or DNA polymerase (97). 
Subsequent viruses have been developed taking into account the deletion of protein ICP34.5, 
found to be a neurovirulence factor, determines a high grade of attenuation and causes the block 
of viral replication and spread in CNS with a low replication in peripheral tissue. The ICP34.5 
deleted viruses are avirulent on intracerebral inoculation of mice and are unable to establish 
latent state after infection due to removal of part of LATs (73, 98). ICP34.5 maps in the inverted 
repeats flanking the long unique sequence of HSV DNA and therefore it is present in two copies 
in the viral genome. Its product blocks the shut-off of host cell protein synthesis induced by viral 
infection and counteracts the protein kinase R (PKR) that is responsible for phosphorilation of 
the eukaryotic translation initiation factor 2 (eIF2 α). ICP34.5  antagonizes PKR by recruiting 
the protein phosphatase 1 that dephosphorylates eIF2a and restores late viral protein synthesis 
(73). HSV γ134.5 mutants include 1716, in strain 17, and R3616 based on strain F. A potential 
drawback is that they replicate less efficiently with lower viral yield compared to wt (97).  
HSV 1716 was developed by MacLean and coworkers (99) on  the wild type strain 17 backbone. 
It carries the deletion of both copies of γ134.5 gene and replicates only in actively dividing cells. 
In vitro and in vivo studies have shown its selective replication and cytolytic activity in a variety 
of tumor types including glioma, medulloblastoma, melanoma, human embryonal carcinoma, 
mesothelioma and non small cell lung carcinoma.  
Intratumoral injection of HSV-1716 at a dose of 105 pfu or 5x105 into an oral squamous cell 
carcinoma (SCC) is safe but with little biological activity (100). To date, there are four cancer 
types in which HSV-1716 is used in clinical trials (73). In general, the virus is well tolerated but 
shows little viral replication due to the low doses used.  An upcoming trial will include 
increasing doses or repeating treatments (73).  
Double mutated o-HSV 
NV1020  (named also R7020) carries the deletion of a 15-kb region at the UL/S junction 
encompassing one copy of the diploid genes α0, α4, and γ134.5 encoding the proteins ICP0, 
ICP4, and ICP34.5, respectively, and one copy of UL56, the protein product of which has not 
been fully characterized but is thought to be involved in neuroinvasiveness of HSV-1  It was 
originally designed to be a vaccine against HSV-1 and HSV-2 infection but it provided 
unsatisfactory results. The removed region was replaced with a fragment of HSV-2 US DNA 
(US2, US3, gJ and gG) creating an intertypic recombinant (97). NV1020 has been used as an 
oncolytic agent against various non CNS tumors like prostate and head and neck (97, 101). The 
virus is replication competent but highly attenuated (101). It is the first engineered HSV 
administered through vascular infusion for treatment of human cancer in a phase I trial. Using an 
intra arterial pump (hepatic artery), NV1020 was injected in 12 HSV seropositive patients with 
liver metastases derived from a primary colorectal tumor (three cohorts 3x106, 1x107 and 1x108 
pfu). All the enrolled patients had previously failed chemotherapy. One month after virus 
administration they started an intra arterial chemotherapy (floxuridine plus dexamethasone). The 
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virus was well tolerated, made the tumors responsive to chemotherapy again and show biological 
activity with tumor size reduction, decrease in carcinoembryonic antigen (CEA, colorectal tumor 
marker) and lack of immunoreactivity (101). The results of a phase II study on liver metastases 
has been reported by Geevarghese et al., (102). Patients treated with NV1020 showed hepatic 
metastases stabilization and have become sensitive to chemotherapy again. After one month 
from the first virus infusion it is noteworthy that a considerable increase in NV1020 
neutralizing antibody occurred without significant adverse effects. 
G207 derives from strain F and is deleted in both copies of ICP34.5 and has a LacZ insertion 
within UL39 (ICP6) locus causing its inactivation. UL39 encodes the large subunit of 
ribonucleotide reductase that is required for nucleotide synthesis in quiescent cells like neurons 
while its enzymatic function is balanced by its cellular enzyme counterpart in rapidly dividing 
cells (73, 103). The intracerebral inoculation of G207 in murine and simian primates was not 
pathogenic.  It was the first oncolytic HSV admitted to clinical trials in the United States (104). 
The safety of G207 has been documented in a phase I trial involving 21 patients with recurrent 
glioma, treated with stereotactic administration up to the highest possible dose (3x109 pfu). No 
acute, moderate or severe toxicity were observed and the maximum tolerated dose could not be 
determined (104). The first clinical study had some limitations (e.g. single site of inoculation, no 
in vivo assessment of viral replication) that were overcome in a phase Ib clinical trial in recurrent 
malignant glioblastoma. The study aimed to confirm virus safety after direct cerebral injection 
adjacent to the tumor or the resected tumor, and after multiple-injections as well as the virus 
spread into the tumor and the degree of patient immune response (105). The study was conducted 
on six patients with recurrent glioblastoma. The virus was administered through a catheter 
stereotactically implanted into the tumor. First, 13% of a total dose of 1.15*109 pfu was injected; 
second, either 2 or 5 days later the tumor mass was resected and the remaining part of G207 was 
injected in the brain surrounding tumor cavity. G207 infected and replicated and the patient who 
showed the highest grade of replication had the longest survival. Seroconversion of three 
seronegative patients occurred and there was immunohistochemical evidence of lymphocyte 
infiltration into the tumor following G207 administration (93, 105). 
G47∆ derives from G207 and carries an additional deletion in the α47 gene. The protein ICP47 
is responsible for inhibiting the transporter associated with antigen presentation (TAP). In 
infected cancer cells, ICP47 deletion induces an increased expression of MHC class I and  
consequently enhanced antitumor immunity through antigen presentation (24). The deletion 
places the late US11 gene under control of the immediate-early α47 promoter. US11 product   
suppresses the reduced growth properties of γ34.5-deficient mutants, precluding the shutoff of 
protein synthesis (9, 106). In most of the cell lines tested, G47∆ replication is better than G207 
with an increased viral yields and a greater cytopathic effect (104). G47∆ efficacy was seen in 
different animal models of several tumors (breast, prostate, brain) (104). Recently the 
combination of G47∆ and the alkylating agent temozolomide (TMZ) has been seen acting 
synergistically in killing glioblastoma stem cells (GSCs) in mice with GSC-derived intracranial 
tumors (107). Moreover systemic administration of G47∆ by tail vein injection was effective in 
inhibiting the growth of established breast cancer lung metastases in Balb/c nude mice (108). In 
Japan, a clinical trial of patients with recurrent glioblastoma is ongoing (104).   
A limitation of ∆γ134.5 HSV is that protein synthesis and replication are limited, and a 
concerning situation is the heterogeneity of the tumor. ∆γ134.5 HSV is effective in tumor with a 
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low PKR activity but certain type of tumor present high activity of this enzyme. The expression 
of PKR has been seen to correlate inversely with MAPK/ERK kinase (MEK) expression. 
Cell lines transducted with a constitutively active MEK were susceptible to R3616 that carries 
the deletion of both copies of γ134.5 in strain F backbone. The virus, administered by systemic 
delivery (intra-peritoneum), showed greater oncolytic activity in xenografted tumors with higher 
level of MEK compared to tumors with low expression of MEK (109). 
To overcome the problem of MEK expression, two recombinant HSV (C130 and C134) were 
generated carrying inhibitors of PKR activity TRS1 and IRS1 respectively  in place of γ134.5 
gene. The two viruses were able to restore late viral protein synthesis and did not show 
neurovirulence. Their antitumor activity was greater than in parental virus at lower doses; 
improved survival was demonstrated in a human malignant glioma in severe combined immune 
deficient (SCID) mice and a syngeneic immunocompetent murine neuroblastoma model (110). 
Armed HSV: as mentioned before, HSV has the advantage of being able to host large transgenes 
in its genome. The introduction of cytochines into HSV should augment the antitumor immunity 
induction and potentiate cancer clearance. Viruses with IL4 in place of  γ134.5 gene showed 
higher antitumor activity and increased survival of mice with intracranial tumors. 
Immunohistochemical analyses for tumor revealed infiltration by macrophages and CD4+ and 
CD8+ T cells (73, 104, 111). 
IL-12 is another cytochine employed for boosting  local immune response. It is expressed by 
cells that present antigen, lymphocytes B and monocytes. One of its properties is to enhance 
oncolytic activity, recruiting natural killer cells and cytotoxic T lymphocytes, as much as the 
development of a TH-1-type immune response mediated. A likely second mechanism for its 
antitumor activity  is its antiangiogenic properties (74). Two HSV have been engineered to 
express and secrete IL-12.   
M002 is a conditionally replication competent virus generated through the deletion of both 
copies of γ134.5 which were replaced with murine IL-12 (74). It was tested in murine brain 
tumors (neuroblastoma) through stereotactic injection and it showed an increase of the median 
survival time of mice compared to controls. The immunostatining of explanted brain tissues 
revealed a great infiltration of CD4+ lymphocytes as well as CD8+ cells and macrophages (74). 
NV1042 was generated from NV1020 with the introduction of murine IL-12 in the deletion of 
the joint region of the long and short sequence (112). It was evaluated in preclinical studies of 
several cancer types e.g. murine model of prostate cancer, colorectal cancer, colorectal metastatic 
liver cancer and prostate cancer that creates metastasis in the lung (113-115). The results of 
experiments in transgenic TRAMP mice, that develop primary tumor spontaneously or metastatic 
prostate cancer, showed the efficacy after intravenous (i.v.) administration. In particular the virus 
was able to reduce the frequency of tumor growth and the formation of lung metastases (113). 
Compared to NV1034, a virus that shares the same backbone but expresses GM-CSF, NV1042 
has  higher oncolytic activity at low doses for intratumoral injections in colorectal cancer (115). 
Another cytokine used in arming HSV has been the granulocyte-macrophage colony-stimulating 
factor. It acts as a differentiation promoter in monocytes, macrophages, neutrophils and 
eosinophils from myeloid precursors cells and stimulates the proliferation of dendritic cells. It 
also acts as a vaccine adjuvant by stimulating the expression of IL-1 and acting as a growth 
factor for antigen presenting cells (116). Thus, in oncolytic virotherapy GM-CSF may contribute 
in enhancing the immune response induced by cells lysed after infection.  
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Oncovex  is an attenuated HSV 1 derived from a fresh clinical isolate (JS-1) to avoid the use of 
laboratory strains that after many passages may have lost some of their oncolytic potential (24). 
The virus carries the deletion of  ICP47 and both copies of γ134.5 replaced with GM-CSF (117). 
Oncovex has already been tested in phase I clinical trials in several tumor types (breast, 
melanoma, coloretal, head and neck cancer) showing significant antitumor effect (117). The 
phase II studies have been completed in metastatic melanoma with many injections (about 108 
pfu up to 24 administrations in some cases). In general, virus administration showed increased 
survival percentage of patients with low side effects. The most important result was the efficacy 
in sites distant from virus injection pointing out a systemic anti tumor immunity (118). 
Considering the results obtained, the phase III clinical trial has been promoted.  
Retargeted o-HSV: A correlated problem to attenuated HSV vectors has been their low 
replication in dividing cells as well as their poor ability to kill tumor cells at low doses(119). The 
viral spread is also reduced and because these viruses cannot overcome host defenses in normal 
cells their activity depends in large part on the tumor genotype.  A different approach has been to 
create replication competent non attenuated viruses targeted to tumor specific receptors. A 
selective tropism should make viral attenuation not as necessary (73). This goal has been 
achieved through modifications that impaired the first viral step of life cycle like attachment and 
binding to cellular receptors. Deletion of HS binding sites on gC (N-terminal) and gB (polylysine 
tract) removes the ability of HSV to bind glycosamminoglicans on cell surfaces.  The first 
attempt to retarget HSV in this way was obtained through the deletion of an HS binding site 
followed by the fusion of N-terminal of gC with erythropoietin (EPO) (120). The resulting virus 
KgBpK-gC- was not able to make a productive infection but showed a reduced ability to bind 
GAG, a specific binding to EPO receptor and an acquired ability to stimulate EPO dependent cell 
lines (FD-EPO) (24, 121). However, gD of EPO retargeted virus could still interact with its 
cognate receptors. 
 
Retargeting through  genetic engineering of gD fused to a heterologous molecule was used to 
modify the spectrum of HSV receptors. The IL13αR  is expressed  in  malignant glioma and can 
be a good target for oncolytic virotherapy. R5111 is a non attenuated replication-competent virus 
that carries IL-13 between aa 24-25 of gD (119).  The virus is able to enter cells that express 
IL13α2R but it still retains the ability to infect through HSV receptors. R5141 is a further 
modification of R5111 in which the ability to use nectin-1 and HVEM has been ablated by the 
deletion of the signal peptide of gD, the deletion of its first 32 aa, and the introduction of the 
amino acid substitution V34S. The retargeting was achieved introducing the sequence of IL13 in 
1-32 deletion. R5141 was able to infect cells expressing IL13α2R and not cells expressing 
nectin-1 or HVEM separately (122). R5181 was another virus engineered according to the same 
strategy  through the insertion of urokinase-type plasminogen activator and no deletion in gD 
gene. UPAR is expressed in glioma cells and differently from IL13 receptor has not a 
transmembrane domain but binds to membranes through a GPI anchor. The virus can interact 
with cells expressing only uPA receptor, but retains its natural tropism. However, these were 
proof of the principle that the retargeting of HSV is feasible and can be applied to retarget HSV 
to a number of tumor specific receptors (with or without transmembrane and cytoplasmatic 
domain). R5181 was further modified to make it similar to the IL13 recombinant virus R5141. In 
this attempt it was discovered that the 61-218 sequence do not execute a function required for 
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HSV-1 entry into cells. Based on these demonstrations Menotti et al. constructed fourth 
generations of  HSV retargeted to HER2 receptor through a scFv anti HER2 (44, 80, 123). The 
characteristics of this receptor will be discussed in the next chapter.  The first recombinants 
obtained were R-LM11 and R-LM11L (123), carrying the  scFv against HER2 between aa 24-25 
of gD.  They were able to infect cells expressing HER2 as a sole receptor but retained the ability 
to enter in J-nectin-1 cells. The first recombinants demonstrated that it is possible to exploit the 
characteristic of antigen-antibody binding to retarget HSV. In addition, it surprisingly 
demonstrates that gD is able to tolerate large insertions as the scFv is as large as gD itself.  The 
second and third generation of retargeted HSV consist of  viruses carrying single or multiple 
mutated residues responsible for binding to nectin-1, in particular D215G, R222N, F223I and 
V34S substitutions (R-LM39). The mutations did not work in ablating the binding to nectin-1, in 
fact R-LM39 was still able to infect cells expressing the receptor. The fouth generation 
engineering was based on knowledge inferred by the 3-dimensional structure of gD: it was 
supposed that the insertion of a large insert such as scFv in the deletion of aa 6-38 of gD could 
sterically mask the nectin-1 binding site better than the previous position (between 24-25) which 
was lateral to the site of interaction. Moreover, the scFv size could make the interface between 
virus gD and nectin-1 inaccessible.  The resulting virus R-LM113 confirmed the hypothesis, in 
fact it was completely retargeted to cells expressing HER2 as sole receptor (80). Furthermore, it 
showed to be fully detargeted from both nectin-1 and HVEM.(37, 44) 
  
 
Table 1.2  - O-HSV generated and applications in oncolytic virotherapy 
 
Oncolytic HSV Engineered mutation(s) Tumor type Clinical trials Ref 
dlsptk tk-   (96) 
HSV1716 γ134.5 gene deletion (both 
copies in strain 17) 
Recurrent 
glioblastoma 
 
 
Metastatic melanoma 
Oral squamous cell 
carcinoma 
 
Completed: I and 
I/II. 
 
 
Completed pilot 
 
Completed: II 
(124) 
 
 
 
(125) 
 
(100) 
R3616 γ134.5 gene deletion (both 
copies in strain F) 
Pancreatic cancer  (126) 
NV1020 15 kbp region in UL/US 
junction (deletion of α0, α4, 
γ134.5 and UL56 genes)  
Prostate  
Head and Neck 
 
Colorectal cancer 
liver metastases 
failing the first-line 
chemotherapy 
 
 
 
 
 
Completed:I and II 
 
 
 
(102, 127) 
G207 γ134.5 gene deletion (both 
copies in strain F), UL39 
Recurrent 
glioblastoma 
Completed: I and 
Ib/II 
(105, 128) 
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deletion 
G47∆ γ134.5 gene deletion (both 
copies in strain F), UL39  and 
α47 genes deletion 
Glioblastoma  Ongoing (104) 
M002 γ134.5 gene deletion replaced 
by mIL-12 
 
 
Glioma  
 
 
(129) 
NV1042 15 kbp region inUL/US 
junction (deletion of α0, α4, 
γ134.5 and UL56 genes) 
replaced by mIL12 
Prostate, colorectal, 
colorectal cancer 
liver metastases and 
prostate cancer lung 
metastases 
 
(97, 113, 
115) 
Oncovex ICP47  deletion and both 
copies of γ134.5 gene 
deletion replaced by GM-
CSF 
Solid tumors with 
cutaneous and s.c. 
tumor deposits 
 
Head and Neck 
cancer 
 
Unresectable stage 
IIIc/IV melanoma 
 
 
Completed: I 
 
 
 
Completed: I/II 
 
 
Completed: II 
 
 
 
(130) 
 
 
 
(131) 
 
 
(132) 
 
 
 
1.9  Tumor specific receptors 
 
1.9.1 HER2 receptor 
 
The human epidermal growth factor receptor 2, called also ERBB2, HER2/neu or c-erbB2, is a 
type 1 transmembrane tyrosine kinase belonging to a closely related family of 4 cell surface 
receptors (ERBB 1, ERBB 3, ERBB 4). HER2, as all other members of the ERBB family, 
consists of an extracellular ligand binding domain, a single α-helical transmembrane portion and 
a cytoplasmic tyrosine kinase domain. The extracellular portion is in turn subdivided into four 
domains (Fig. 1.9). Domain I and III are normally involved in peptide binding whereas the 
domain II is essential in homo- or heterodimerization that triggers the internal signaling cascade. 
The HER2 distinctive feature is how the domains are spatially organized in the ectodomain. In 
absence of ligands, ERBB1, ERBB3 and ERBB4 take on a close conformation where domain II, 
located near domain IV, is not available to take contact with other receptors. Conversely, HER2 
exists in a fixed open conformation that is similar to ligand-activated receptor state: the 
interaction between domain I and III is present while the domain II−IV interaction does not 
occur. In this way domain II results constitutively exposed (Fig. 1.9) (133). This arrangement 
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makes HER-2 unable of binding to a ligand and a suitable partner for heterodimerization with 
other family members. ERBB3 receptor seems to be the favorite.  
HER2 has the strongest catalytic kinase activity and HER2-containing heterodimers have the 
strongest signaling activity (134). The HER2 dimerization activates signaling cascade that 
regulate cell proliferation, survival,  invasion and angiogenesis (Fig. 1.10) (135). In particular, 
HER2 activation and signaling play an essential role in embryogenesis of the heart demonstrated 
by the fact that embryos lacking of HER2 receptor die for the onset of myocardium dysfunction 
in the maintaining of blood flow (136). HER2 is poorly expressed in normal adult tissues with 
the exception of the heart. 
 
 
 
 
Figure 1.9 – Domain organization of  ERBB receptor family.  ERBB1,ERBB3 and ERBB4 exist in a closed conformation 
where in absence of ligand the domain II is not exposed and not available for the interaction with other receptor. ERBB2 exist in 
an open conformation permanently available for dimerization (137).   
 
 
A potent mitogen signal is associated with HER2 receptor activation. The receptor is able to bind 
to a great amount of phosphotyrosine-binding proteins such as the growth-factor-receptor bound-
2 (GRB2) and Src-homology-2-containing (Shc) (Fig. 10). These adaptor proteins mediate in 
turn the recruitment of Ras and activation of the mitogen-activated protein kinase (MAPK) 
cascades. This signaling lead to activation of transcription factors which regulate  genes that 
affect various cellular function (Fig. 10) Furthermore, heterodimers containing HER-2 show an 
enhanced affinity and specificity to several ligands (133).  
HER2 receptor was found to be overexpressed in about 18-25% of human breast cancers and its 
amplification occurred also in ovarian cancers, gastric carcinoma, a small proportion of non-
small cell lung tumors and salivary gland tumors (137). HER2 amplified breast cancer are 
characterized by an increasing in proliferation rates, more aneuploidy, tendency to metastasize to 
CNS and viscera, resistance to endocrine therapy as well to a poor prognosis (134).  Breast 
cancers can arrive up to 25 to 50 copies of the HER2 gene and up to a 40 to 100 fold increase in 
HER2 protein. The difference in expression between tumor and healthy tissues makes this 
receptor an ideal target for cancer therapy. Early experiments showed that mAb against the 
receptor extracellular domain were able to inhibit  tumor growth in cancer cells overexpressing 
HER2 (137). 
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Two drugs are currently FDA-approved for treatment of HER2-positive cancers. 
Trastuzumab is a humanized monoclonal antibody that recognizes the domain IV of HER-2 
extracellular domain. It seems to affect highly tumors with increased HER2 homodimer. The 
mechanism of action is still unclear but it seems to inhibit the receptor signaling, to disrupt 
HER2/Src interaction as well as to cause the internalization and downregulation of the receptor.  
This antibody was used in combination of chemotherapy with promising cytotoxic results. For 
example doxorubicine is more effective in combination with trastuzumab because of 
coamplification with HER2 of its target topoisomerase 2 (134). Several large clinical triasl have 
shown that administration of trastuzumab in the initial adjuvant (post-surgical) setting in 
combination or sequentially after chemotherapy results in an improvement in disease-free 
survival with a 50% reduction of the risk of relapse as well as overall survival (137). 
Lapatinib is an oral small inhibitor of tyrosine kinase activity of HER1 and HER2. It is effective 
in tumors resistant to trastuzumab as showed by a phase III study in which patients who had 
previously failed therapy with anthracycline, taxane and trastuzumab had a significant 
improvements after lapatinib administration in combination with capecitabine (135). 
Trastuzumab and lapatinib are also synergistic in preclinical models, suggesting that these agents 
could be combined in the clinic (138). 
Other monoclonal antibodies against HER2 are under investigation to be used as therapeutic 
agent. Pertuzumab (Genentech/Hoffmann-La Roche) is a humanized monoclonal antibody that 
binds to an epitope in domain II. It acts through the inhibition of singaling cascade and ihas 
shown excellent activity in vitro against several breast cancer cell line that express ERBB 
ligands and in vivo against human breast cacner xenograft tumors (137).  
One of the last therapeutic approach for HER2 positive tumor is the use of scFv  antibody that 
bind specifically to the receptor. Recently recombinant immunotoxins, consisting of single-chain 
variable fragments (scFv) anti-Her2/neu fused to recombinant gelonin (rGel) were evaluated for 
the effect on antitumor efficacy and off-target toxicity in vitro (139). 
 
 
 
Figure 1.10 - Signaling cascade after HER2 dimerization. After ligand binding, dimerization occurs leading to activation of 
the intracellular tyrosine kinase. HER2 can create homo or heterodimers with other members of HER family. FKHR, forkhead in 
36 
 
rhabdomyosarcoma; Grb2, growth factor receptor- bound protein 2, GSK-3 glycogen kinase synthase-3; MAPK, mitogen-
activated protein kinase; mTOR, molecular target of rapamycin; PI3K, phosphatidylinosito 3-kinase; PTEN, phosphatase and 
tensin homologue deleted on chromosome 10; SOS, son- of sevenless guanine nucleotide exchange factor (135). 
 
 
 
1.9.2 PSMA receptor 
 
The prostate specific membrane antigen (PSMA) is a 100 kDa type II membrane glycoprotein. 
Human PSMA gene was cloned by means of the 7E11mAb from human LNCaP cell line and was 
found to be located in chromosome 11p11-12. The protein consists of an extensive extracellular 
domain, spanning from amino acids 45 to 750, a single hydrophobic transmembrane domain (aa 
20-44) and a short NH2 cytoplasmatic tail (aa 1-19). The extracellular domain is glycosylated  
contributing to 25% of the protein molecular weight (Fig. 1.11).  The short cytoplasmatic tail 
carries a short internalization motif MXXXL. The receptor undergoes internalization and 
recycling at high rate especially when it is bound by antibody J591(140). The PSMA 
endodomain interacts with actin binding Dilamin a (FLNa) that maintain the receptor anchored 
to plasma membrane decreasing the internalization rate of 50% (140). PSMA is expressed as a 
non cavalently linked homodimer on the cell surface. And was demonstrated that the 
dimerization is critical to maintaining the conformation and enzymatic activity of PSMA (141). 
PSMA has different names that reflect its role in several cellular pathway as in prostate 
carcinogenesis and progression, glutamatergic neurotransmission and folate absorption (140). 
PSMA name derived from its strong expression in the prostate, NAALADase is due to its ability 
to metabolized the N-acetyl-aspartyl-glutamate neurotransmitter in the brain, folate hydrolase 
FOLH1 because it removes glutamates form poly-g-glutamated folate in the small intestine and 
is also named glutamate carboxypeptidase II, GCPII as a carboxypeptidase (140).  
PSMA is mainly expressed in glandular cells of the secretory acinar epithelium in normal 
prostate and  immunohistochemical analysis revealed its expression also in kidney, brain, 
skeletal muscle, colon heart or breast(142), even if the staining is much less intense than in 
prostate. The amount of PSMA in these tissues was estimated three orders of magnitude less than 
in prostate (141). 
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Figure 1.11 – Schematic PSMA structure  The type 2 transmembrane protein consists of a small intracellular domain (CD), a 
single hydrofobic transmembrane domain (TM) and a large ectodomain (ED).  A- endocytic targeting motif and filamin A (FLNa) 
binding site. Y- nine predicted ectodomain N-glycosylation sites. B-D- domains of unknown function that encompass aa 44-150 
and 152-274 respectively. C-E proline  and glycine rich regions. F-G- catalytic domain aa 274-587 and a final domain of 
unknown function form 587 to 750 with a helical dimerization domain (141). 
 
 
The receptor has been described several times upregulated in prostate cancer and its increase 
correlates with more aggressive tumor forms (143). The analysis of resected tumors showed that 
high expression of PSMA matched with high relapse percentage in short time. PSMA is also 
expressed in the tumor-associated neovasculature of solid tumors while it is absent in normal 
vascular endothelium. The anti PSMA antibody J591 has successfully employed to targeting 
neovasculature of solid tumors in vivo. In a recent paper Wrenicke et al. reported that 32 
specimens from GBM patients exhibited positive staining for PSMA (144). 
PSMA expression was found to be suppressed by androgen (145). This feature makes it a good 
target as a therapeutic agent because normally patients undergo androgen deprivation therapy. 
PSMA has been exploited as antigenic target for a variety of clinical application because of its 
large ectodomain and specific tissue expression. ProstaScint© (Citogen)  was the first mAb FDA 
approved as imaging molecule. It binds to an intracellular epitope highlighting only dead or 
necrotic cell and this feature was used to reach viable cells in proximity to dying tumor cells in 
soft tissues (143). It is less effective in identifying bone metastases because low dead cell 
percentage is present (141). The second generation of antibodies is still under investigation. 
J591, a humanized monoclonal antibody against the extracellular domain of PSMA  was 
conjugated with radionuclides and cytotoxic drugs (146, 147). The scFv to PSMA derived from 
J591 has been employed as targeting agent in measles virus. scFv was inserted as a C-terminal 
extension on the MV attachment protein. The PSMA virus induced tumor regression of LNCaP 
and PC3-PSMA tumor xenografts (148). It has recently been reported that J591 linked to the 
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saporin toxin of  Saponaria officinalis  shows a potent and selective antitumor effects on PSMA-
positive cells in vitro and in vivo (149). Moreover, this antibody labeled with a 177 LU is still in 
phase II trials (150). 
PSMA likely has a role in cell adhesion in fact PSMA expressing cells are resistant to proteolytic  
disassociation when grown on bone marrow matrix. This feature could explain why bones are the 
preferential site of prostatic metastases (151). 
 
1.9.3 EGFRvIII receptor 
 
As mentioned in 1.9.1 paragraph, epidermal growth factor receptor (EGFR , Erbb1 or HER1), a 
170-kDa transmembrane glycoprotein belongs to a closely related family of 4 cell surface 
receptors. EGFR is involved in cellular proliferation pathway and has a trophic effect on several 
cells. Wt EGFR gene amplification occurs with 36% to 40% of frequency in GBM and its 
expression at high levels correlates with various types of cancer (152). Of this 36% - 40% more 
than a half has rearrangements of the EGFR gene The specific mutant form of EGFR receptor, 
EGFRvIII, is highly expressed on many glioblastomas, breast carcinomas, and other tumors and 
is associated with increased invasiveness and growth rate of tumors.  This mutated receptor 
forms resulted in the deletion of exons 2 to 7. The result is an in frame deletion of 26 amino 
acids from the ectodomain of the receptor (Fig. 1.12). In place of the deletion a glycine codon, 
absent  in the protein wt form, is generated. This transcript arises from an aberrant splicing 
explains why the sequence is the same despite the variable sequence losses in the amplified 
genes (153). Several antibodies have been described that are specific to EGFRvIII and do not 
cross-react with wild-type EGFR (154).  EGFRvIII expression has no effect on survival of GBM 
patients but is predictive of GBM-like clinical behavior. The deletion in EGFRvIII ectodomain 
results in a constitutive tyrosine kinase activity because the receptor in unable to bind any known 
EGFR ligand (155).  
 
 
 
 
 
Figure 1.92 - Comparison of the structures of the EGFR and EGFRvIII. The EGFRvIII variant receptor is characterized by a 
deletion of exons 2–7 of the wild type (Wt) EGFR gene. A new glycine residue is inserted at the fusion junction. 
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EGFR does not appear to be ever present in not trasformed tissues, appearing as a completely 
specific tumor marker, expressed in high quantities enough to be a potential therapeutic target. 
The ectodomain deletion abolishes the receptor ability to interact with the ligands but makes it 
able to dimerize stably. The constitutive activation resulting in activation of the kinase domain 
resulting in  stable phosphorylation of tyrosine residues on the C-terminal tail. 
The internalization of EGFRvIII is reduced compared to the wt form of the receptor probably 
due to the absence of the ligand. In this way, the mutated receptor has a longer residence time on 
the cell surface, prolonging its effect signaling. In vivo it was highlighted that EGFrvIII confers a 
greater proliferation capacity and a cellular resistance to apoptosis. This ability seems to result 
from preferential activation and signaling mediated by PI3K, as regards the resistance to 
apoptosis appears to be involved the Bcl-XL activation ( member of the Bcl-2) (155) (Fig 1.13). 
 
 
 
 
Figure 1-13 - The epidermal growth factor receptor (EGFR)vIII confers enhanced glioblastoma multiforme (GBM) 
tumourigenicity through several key mechanisms. The EGFRvIII receptor increase cell proliferation through promotion of 
PI3K/Akt signalling; Shc and Grb2 association and Ras activity while inhibiting cell cycle regulators such as p27KIP1 and 
upregulating abnormal spindle-like microcephaly-associated (ASPM) expression. Furthermore, EGFRvIII promotes survival in 
cells by increasing expression of anti-apoptotic proteins such as Bcl-XL, and enhances angiogenesis and cell invasion by un-
regulating vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and matrix metalloproteinase 13 (MMP13) 
expression. Red lines with blunt ends indicate inhibitory effects; black lines with arrow heads indicate stimulatory effects. 
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2. Objective 
 
The aim of this thesis has been the genetic engineering, characterization and anti-tumor efficacy 
in vitro and in vivo of oncolytic HSVs retargeted to tumor specific receptors. Retargeting implies 
the modification of viral tropism in order to make HSV-1 able to recognize and bind only to the 
cancer receptors for which it was engineered. At the same time the HSV-1 was rendered unable 
to recognize its natural receptor (detargeting), HVEM and Nectin-1 (Fig. 2.1). In particular, three 
tumor cancer-specific receptors were selected: HER-2 receptor, highly expressed in ovarian,  
breast cancer  and in glioma multiforme (viruses R-LM249 and R LM113 and R-LM291); PSMA 
receptor (virus R-LM593), over-expressed in prostate cancer and neovasculature of solid tumors; 
and EGFRvIII (virus R-LM613), expressed in gliomas. 
The devised strategy has made use of (i) in-depth knowledge of glycoprotein gD of HSV, which 
determines viral tropism, (ii) the availability of single chain antibodies against the examined 
receptors and (iii) technology for o-HSV-1-BAC engineering.  
Receptor specific single chain antibody was inserted in gD in two positions: N-terminus 
(deletion 6-38) in R-LM249 and R-LM291 or in place of the immunoglobulin core (deletion 61-
218) in R-LM113, R-LM593 and R-LM613.   
I describe: 
(i)  R-LM249 genetic engineering to HER2 retargeting and its efficacy against ovary and 
breast tumor in vivo; 
(ii) R-LM113 (HER2 retargeted) efficacy against glioblastomas; 
(iii) R-LM291 (HER2 retargeted) genetic engineering to introduce two mutation in gB for the 
purpose of improve rate of entry in HER2 positive cancer cells; 
(iiii) R-LM593 genetic engineering to prostate specific membrane antigen (PSMA) and in vitro 
characterization; 
(iiiii) R-LM613 genetic engineering to epidermal growth factor receptor variant III (EGFRvIII) 
and in vitro characterization. 
 
 
 
Figure 2.1 - Tropism of an oncolytic HSV detargeted from its natural receptors , HVEM and Nectin-1 and retargeted to a cancer 
specific receptor, as compared to the tropism of wt HSV (156). 
41 
 
 
3. Material and Methods 
 
3.1 Cells 
 
In this research these cells have been used: 
 
HER2 positive cells 
Human: SK-OV-3 (human ovarian adenocarcinoma), SK-BR-3,  BT-474 and MDA-MB-453  
cells (human mammary adenocarcinoma) express HER2 at high levels. MCF-7 cells (human 
mammary adenocarcinoma) have an intermediate HER2 expression level.  
Murine: D2F2/HER2 cells are BALB/c mouse mammary tumor cells transduced with the 
huHER2 gene and 1E-huHER2 cells are a murine mammary carcinoma cell line transduced with the 
huHER2 gene. FVB 6443.0 cells derived from explanted tumor of a FVB/N HER-2/neu 
transgenic mouse (Genentech). TT12E2 (mammary carcinoma of rat HER-2/neu transgenic 
mice) express high levels of rat HER2/neu and were use a negative control. 
 
Hamster: J-HER2 cells derived from J cell stably transfected with plasmid encoding HER2 
receptor (79). 
 
PSMA positive cells 
LNCaP-FGC (human prostate carcinoma) have a high level of PSMA expression.  
J-PSMA cells derived from J cell stably transfected with pIRES-PSMA plasmid. 
 
EGFRvIII positive cells 
U251-EGFRvIII is a human glioblastoma cell line transfected with pcDNA-EGFRvIII 
J-EGFRvIII cells are derived from J cell transfected with pcDNA-EGFRvIII  
 
Other control cells 
Human: HEp-2 (human epithelial cells), U251 (human glioblastoma cells), I-143tk- (human) was 
a derivative the thymidine kinase (tk) positive cell lines R970-5 by selection with BrdUrd (157). 
SJ-Rh4 (human rhabdomyosarcoma) do not express HER2 and were used as negative control. 
Murine: L (mouse fibroblasts), NIH3T3 (mouse fibroblasts). 
Hamster: BHK (baby hamster kidney), J cells are derived from BHK tk-. They lack of Nectin-1 
and HVEM receptors and are resistant to HSV infection (61). 
The following cell lines were generated from J cells after transfection of single receptors: J-
Nectin-1, J-HVEM, J-EGFR. They are maintained under constant selection with G418 (400 
g/ml). 
Rabbit: Rabbit skin (RS), RGDp6 (RS expressing glycoprotein D under the control of HSV late 
promoter γUL26.5) (80). 
Simian: Vero (green monkey kidney cells).  
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Cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 5-10% 
FBS (Gibco), PenStrep (1%; Euroclone) except for SK-OV-3, BT-474, MDA-MB-453 that were 
grown in RPMI 1640 Ultraglutamine (Lonza) supplemented with PenStrep and 10% FBS heat 
inactivated at 56°C for 30 minutes. All cells were maintained at 37°C in 5% of CO2 atmosphere. 
 
 
3.2 Construction of cell lines expressing heterologous receptors 
 
J cells were transfected with pIRES-PSMA, pcDNA EGFR and pcDNA EGFRvIII to generate J-
PSMA, J-EGFR and J-EGFRvIII respectively. Cells were selected with neomycin G418 at a 
concentration of 400 to 800 µg/ml for 5 days. Single clones were obtained by limiting dilution 
and were checked for membrane expression of heterologous receptor by indirect 
immunofluorescence (IFA) with mAb 9G6 (Santa Cruz) for HER2, mAb PMSA cl 1071A4 
(MBL), mAb sc-120 for EGFR and EGFRvIII (Santa Cruz) diluted 1:50 in 20% newborn calf 
serum (NCS) in phosphate-buffered saline (PBS), followed by fluorescein isothiocyanate 
(FITC)-conjugated anti-mouse IgG (Jackson Immunoresearch). 
 
3.3 Plasmids 
 
pGalK carries the coding sequence of galK enzyme and is described in ref. (158).  
 
pMR1-ENV1 carries the nucleotide sequence of scFv to EGFRvIII. The plasmid was kindly 
provided  by Ian Lorimer, Ottawa Health Research Institute and was described in (159). 
 
pSL1180-scFv-PSMA contains the nucleotide sequence of scFv (J591) to PSMA. The plasmid 
was kindly provided by Micheal Sadelain, Memorial Sloan-Kettering Institute (160). 
 
pIRESneo-PSMA was kindly provided by Angelo Baccala, Cleveland Clinic. 
 
pcDNA-EGFR I isof a was generated by amplification of EGFR receptor coding sequence from 
genomic DNA of CHO-EGFR cells (kindly provided by Steve Russell (161) and  subcloned in 
pcDNA 3.1(-) vector (Invitrogen). A 4000 bp PCR fragment was obtained with primers T7 (5ˈ-
TAA TAC GAC TCA CTA TAG GG_3ˈ) and BGHrev (5ˈ_TAG AAG GCA CAG TCG 
AGG_3ˈ). The fragment was sequenced with the same primers and aligned with submitted 
sequence NM_005228 on GeneBank database. The XbaI and HindIII site were used to subclone 
in pcDNA 3.1(-). Sequence positive EGFR clones were transfected in RS cells and tested for cell 
surface expression of the EGFR receptor by immunofluorescence. 
 
 
 
The EGFRvIII variant receptor is characterized by a deletion of exons 2–7 of the wild type 
EGFR gene. This results in an in-frame truncation of amino acids 6 to 273 in the extracellular 
domain of the full length protein EGFRvIII.  
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pcDNA-EGFRvIII was generated from pcDNA-EGFR. The EGFRvIII conding insert was 
amplified by PCR using a synthetic oligonucleotide to generate the truncated N-terminal region 
of EGFRvIII and to insert a XbaI site. These primers were used: Xba_EGFRvIII_f  (5ˈ_TGT 
GCT CTA GAT GCG ACC CTC CGG GAC GGC CGG GGC AGC GCT CCT GGC GCT GCT 
GGC TGC GCT CTG CCC GGC GAG TCG GGC TCT GGA GGA AAA GAA AGG TAA TTA 
TGT GGT GAC AGA TCA CGG) and BGH rev (5ˈ_TAG AAG GCA CAG TCG AGG). The 
fragment of about 3200 bp was subloned into pcDNA 3.1 (-) in XbaI and HindIII sites. 
Sequence EGFRvIII positive clones were transfected in RS cells and tested for cell surface 
expression of the EGFR receptor by immunofluorescence with mAb anti-EGFR Santa Cruz sc-
120 diluted 1:50 in 20% NCS in PBS followed by fluorescein isothiocyanate (FITC)-conjugated 
anti-mouse IgG (Jackson Immunoresearch). 
 
 
gB D285N A549T was obtained through mutagenesis of wt gB cloned in pcDNA 3.1(-). The 
amino acid substitutions D285N and A549T described in (56) and EcoRI (nt 856-861), NheI (nt 
1651-1656) as silent sites for clone screening were inserted by means of  Quick Change XL Site 
Directed Mutagenesis Kit® of wt gB in pcDNA3.1 (-) with primers gB_D285N_EcoRI_f (5ˈ_ 
GCT CGG TGT ACC CGT ACA ACG AAT TCG TGC TGG CGA CTG GC_3ˈ), 
gB_D285N_EcoRI_r (5ˈ_ GCC AGT CGC CAG CAC GAA TTC GTT GTA CGG GTACAC 
CGA GC_3ˈ), gB_A549T_NheI_f (5ˈ_ GCA AGC TGA ACC CCA ACA CGA TCG CTA GCG 
CCA CCG TGG GCC GGC GGG _3ˈ), gB_A549T_NheI_r (5ˈ_ CCC GCC GGC CCA CGG 
TGG CGC TAG CGA TCG TGT TGG GGT TCA GCT TGC _3ˈ).  
 
 
3.4 Viruses 
 
All recombinant HSV-1-BACs in this research were derived from pYEbac102, which carries 
pBeloBAC11 sequences inserted between UL3 and UL4 (162). 
 
R-LM5 was described in (80) and derived from gD--EGFP-HSV-BAC (Fig 3.3.1 A). R-LM5 is a 
recombinant virus carrying wild-type (wt) gD and an EGFP reporter under the viral promoter 
α27 and was generated by homologous recombination in mammalian cells (Fig. 3.3.1 B).  
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Figure 3.3.1 – Schematic representation of (A) gD minus-EGFP-HSV-BAC and (B) R-LM5 (80).  
 
R-LM113 was described in (80) (Fig. 3.3.2). It was generated from gD minus EGFP-HSV-BAC 
(Fig. 1 A) and carried scFv to HER2 in place of the deletion aa 6-38 of gD. 
 
 
Figure 3.3.10 – gD in R-LM113.  scFv HER2 with a 11aa glycine serine linker was inserted in deletion aa 6-38 of gD. VL and 
VH, light  and  heavy-chain variable domains of the anti-HER2 antibody 4D5 (80). 
 
R-LM249  
 
R-LM249 was obtained by means of 2-step replacement recombination in Escherichia coli 
DH10B strain as described in (44, 163). The pS249 shuttle vector carries the sequence coding for 
a chimeric glycoprotein gD engineered with a single chain antibody (scFv) anti HER-2 flanked 
by serine-glycine linkers (upstream 8 aa residues: HSSGGGSG; downstream 12 aa residues: 
SSGGGSGSGGSG) in place of gD amino acid residues 61 to 218. Mutagenesis and cloning was 
performed on pLM5, a plasmid containing WT-gD plus 500 bp upstream and downstream 
flanking sequences (80). First, 2 NdeI sites were inserted in the coding sequence for gD amino 
acid residues 61–62 and 218–219 of mature gD with mutagenic primers gD_61/62_NdeI_f 
(5ˈ_ACG GTT TAC TAC GCC CAT ATG GAG CGC GCC TGC C_3ˈ) and gD_218/ 
219_NdeI_f (5ˈ_GAC GGT GGA CAG CAT CCA TAT GCT GCC CCG CTT C_3ˈ). Next, an 
oligo encoding a 9 aa serineglycine linker was inserted in place of the sequence encoding amino 
acid 61–218 of gD by annealing and ligating into the NdeI cut vector the 2 phosphorylated oligos 
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P-SG9Bam7/Nde_f (5ˈ_TAG TAG TGG CGG TGG CTC TGG ATC CGG_3ˈ) and P-
SG9Bam7/Nde_r (5ˈ_TAC CGG ATC CAG AGC CAC CGC CAC TAC_3ˈ), containing a silent 
BamHI site. The scFv to HER-2 was amplified from pS2019a (164) with primers scFv_Bam_f 
(5ˈ_GGC TTA TGG ATC CGA TAT CCA GAT GAC CCA GTC CCC_3ˈ) and 
scFv_SG_x37_BamH_r (5ˈ_CGG AGG ATC CAC CGG AAC CAG AGC CAC CGC CAC TCG 
AGG_3ˈ) and inserted into the BamHI site of the serine-glycine linker. Last, the cassette 
containing the engineered gD, plus gD genomic upstream and downstream flanking sequences 
was subcloned to pST76KSR shuttle vector to obtain pS249 for homologous recombination in E. 
coli (Fig. 3.3.3). The recipient genome gD--EGFP-HSV-BAC, carrying EGFP as reporter gene, 
was described in ref. (80). The recombinant virus, designated R-LM249, was reconstituted as 
described in ref. (44). 
 
 
 
Figure 11.3.3 - Schematic representation  of two-step replacement in Escherichia coli DH10B. 
 
R-LM291, R-LM593 and R-LM613 construction 
 
GalK recombineering technology 
 
All the other recombinant HSV-1-BAC viruses reported in this thesis were generated by the galK 
recombineering technique, an efficient galactokinase-based positive/negative selection system 
(galK), that makes it possible to modify BAC DNA via homologous recombination (158). It 
exploits a modified E.coli strain (SW102) deleted for galK that makes bacteria unable to grow in 
medium with galactose as only carbon source. However, the galK function can be added in trans 
restoring the ability to metabolize galactose. Further to this, SW102 strain  carries  prophage 
RED recombination system under the control of a temperature sensitive repressor, cI857, that 
inhibits the expression of recombinases at 30°C. When bacteria are shifted to a temperature of 
42°C recombinases are actively expressed and can mediate the recombination between the HSV-
1-BAC backbone and the insert carrying  transgene flanked by homology sequence arms to the 
target. 
The technology consists of two steps:  first, the galK gene, amplified from pGalk plasmid, is 
inserted in the target site on HSV-1-BAC backbone in bacteria via homologous recombination 
(Fig. 3.3.4A). Bacteria are plated on medium supplemented with chloramphenicol (antibiotic 
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resistance carried by HSV-1-BAC) and galactose as only carbon source, where only positive 
galK clones are able to   grow (positive selection) (Fig. 3.3.4B). Second, through a second 
homologous recombination the galK cassette is replaced by a cloned fragment or PCR product 
carrying the transgene of interest (Fig. 3.3.4C). Electroporated bacteria are plated on medium 
plates supplemented with chloramphenicol the toxic analogue of galactose 2-deoxy-galactose 
(DOG) and glycerol as the sole carbon source. DOG is not toxic for bacteria unless 
phosphorylated by galK. The resulting resistant colonies will be positive for transgene although 
some background is present consisting of bacteria that have lost galK not introducing the new 
transgene (Fig. 3.3.4D).  
 
A
B
C
D
 
Figure 3.3.12 – GalK recombineering technology.  A)  Knock-in of galK cassette in  BAC recipient and B) selection on 
galactose plates. C) Knock out of galK cassette and insertion of DNA fragment of interest. D) Counterselection of recombinants 
on DOG-glycerol plates. cat: cloramphenico acetyltrasferase as BAC selection marker. H1 and H2: homology arms in BAC and 
DNA fragments for homologous recombination .  Modified by (158). 
 
GalK protocol 
galK knockin 
Briefly,  the galK gene is amplified with primers: forward: 5’-50bp-homology CCT GTT GAC 
AAT TAA TCA TCG GCA-3’ and reverse: 5’-50bp-homology-compl-strand-TCA GCA CTG 
TCC TGC TCC TT-3’ following this PCR protocol: 94°C 15 sec, 60°C 30 sec, 72°C 1 min for 
30 cycles. For each 50 µl PCR reaction, 2 µl of DpnI are added, mix and incubate at 37°C for 1 
hour in order to remove any plasmid template. The PCR product is gel extracted with Wizard® 
SV Gel and PCR Clean-Up System (Promega). A single SW102 colony containing the recipient 
BAC is inoculate in 5 ml of LB low salt with chloramphenicol 12.5 g/ml at 30°C. 
The next day 2 ml of SW102 culture are diluted in 100 ml of LB low salt and chloramphenicol 
and shaken at 32°C to an OD600 of about 0.55-0.6. The culture is then divided in two bottles and 
left to shake in waterbath at 30°C or 42°C respectively for 15ˈ. The two samples, hereafter called 
induced and un-induced, are transferred in  pre-cooled 50 ml conical tubes and centrifuge at 
3000 rpm for 8 minutes at 0°C. The supernatant is poured off from both tubes and the pellet are 
resuspended in 5 ml of sterile H2O by gently swirling in ice/waterbath slurry. After resuspension 
H2O is added to 50 ml and tubes are centrifuge again. The last step of resuspension is repeated. 
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After the second washing, the supernatant is completely removed and 50µl of cells are 
electroporated with 30 ng of galK amplificate in a 0,2 cm cuvette (BioRad) at 25 mF, 2,5 kV and 
200 ohms. Bacteria from both induced and un-induced are recovered in 1 ml of LB low salt for 1 
hour at 30°C. Then, bacteria are washed twice with M9 salt 1x and plated on M63 minimal 
media plates supplemented with chloramphenicol 12,5 µg/ml  and  galactose as carbon source. 
Plates are left at 30°C.  
After about 5 days colonies should be visible only in induced bacteria plates. Single colonies are 
streaked into McConkey agar plates, supplemented with 1% of galactose and chloramphenicol 
12,5 µg/ml, to assess the presence of galK (background colonies will be white/colorless). Red 
galK+ colonies are however screened by colony PCR for galK gene presence with primers 
galK_129_f (5ˈ_ACA ATC TCT GTT TGC CAA CGC ATT TGG_3ˈ) and galK_417_r (5ˈ_CAT 
TGC CGC TGA TCA CCA TGT CCA CGC_3ˈ). 
galK knock out 
Before starting it is necessary to amplify, digest with DpnI and purify from agarose gel the insert  
for galK substitution.  
Then, red galk+ colonies from McConkey agar plates are inoculated in 5 ml of LB low salt and 
chloramphenicol 12.5 µg/ml and grown overnight at 30°C. The protocol continues in the same 
manner as the galK knock-inin step until electroporation. Then, 50 µl of electrocompetent cells 
induced and un-induced are electroporated with 200 ng of the amplified insert. The recovery 
occurs by shaking in 10 ml of LB low salt at 30°C for 4 hours. After two washes with M9 salts, 
the bacteria are plated on M63 minimal media plates with chloramphenicol 12.5 µg/ml, glycerol 
as carbon source and DOG 0.2%. 
After 5 days colonies are visible both in induced and un-induced plates with or without a great 
difference in number. This second selection step is less stringent in fact some colonies are 
background bacteria that have lost galK no introducing the transgene of interest.About 30 
colonies are picked up, screened by colony PCR for the desired insert and confirmed by 
sequence analysis. 
 
 
 
Adjustments to galK recombineering  protocol 
Considering the size of inserts used (scFv of about 800 bp), some changes were made to the 
original protocol in order to increase recombination efficiency:  
• Homology arms between insert and target sequence were lengthened to 400 bp instead of 
50 bp. 
• DOG concentration was increased to 0.3% to make the selection of the second 
recombination more stringent 
• In the second recombination step 400 ng of template were used instead of 200 ng. 
 
 
Minimal media and the indicator plates were prepared using following solutions: 
 
Luria-Bertani medium (low salt)  
1%  Tryptone 
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0.5% Yeast Extract 
0.5% Nacl 
for agar plates  0.15%  of Agar is added. 
 
M9 washing solution (1x) 
0.6% Na2HPO4 
0.3% KH2PO4 
0.1% NH4Cl 
0.05% NaCl 
 
M63 solution (5x) 
1% (NH4)2SO4 
6.8%  KH2PO4 
0.0025% FeSO4·7H2O 
adjust to pH 7 with KOH 
 
Gal positive selection:  
1xM63 + agar (15 g/l) + D-galactose (0.2%; Sigma) + D-biotin (1 mg/l; Sigma) + L-leucine (45 
mg/l; Sigma) and chloramphenicol (12.5 µg/ml; Sigma).  
Gal counterselection:  
1xM63 + agar + glycerol (0.2%; Sigma) + D-biotin (1 mg/l) + L-leucine (45 mg/l; Sigma) + 
DOG (0.2%; Sigma) and  chloramphenicol (12.5 µg /ml).  
Gal indicator plates: MacConkey agar (Difco, BD Biosciences) + D-galactose (1%) and – 
chloramphenicol (12.5 µg /ml).  
 
 
BAC-LM291, BAC-LM593 and BAC-LM613 were generated through galK recombineering 
technology (Fig. 3.3.5 and 3.3.6). 
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Figure 3.3.13 - Schematic representation of  BAC-LM291 generation.  A-B) GalK cassette was inserted in gB of R-LM249 
(44) between nucleotides 852-1648, generating the intermediate BAC-LM290. C) BACLM290 becomes BAC-LM291 after 
second step of galK recombineering where galK gene was replaced by D285N-A549T insert (primers in table 2).  
  
 
 
 
 
Figure 3.3.14 – Schematic representation of BAC-LM593 and BAC-LM613 generation. A-B) GalK gene was inserted in 
place of gD locus in gD minus-EGFP-HSV-BAC (80), generating the intermediate gD--galK-EGFP-HSV-BAC. C) BAC-LM55 
carries the repaired wt-gD after second step of galK recombineering on gD minus-galK-EGFP-HSV-BAC. D-E) In order to insert 
scFv anti-PSMA in gD, first galK cassette was inserted between amino acids 6-38 of wt-gD in R-LM56 and subsequently the 
insert was replaced by scFv PSMA in R-LM593 followed by 11GS linker. F-G) In R-LM57, galK gene was inserted in place of 
scFv PSMA leaving the 11GS (glycine-serine)linker inside gD sequence. Then, galK was replaced by scFv anti-EGFRvIII to 
generate R-LM63.  
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Primers used for generation of recombinant viruses in this research are summarized below (Table 
3.3.1 and 3.3.2). 
 
Table 3.3.3- Primers for knock in of galK cassette (DNA template is pGalK (158)). 
 
Primer name Sequence HSV-1 BAC 
gDup_GalK_f TAAGCTTCAGCGCGAACGACCAACTACCCCGATCATCAGTTATCCTTAAGCCTGTTGACAATTAATCATCGGCA gD- galK BG53 
gDdown_GalK_r TGTCCACCTTTCCCCCCTTCCAGACTCGCTTTATATGGAGTTAAGGTCCCTCAGCACTGTCCTGCTCCTT gD- galK BG53 
gD5_galK_f TTGTCGTCATAGTGGGCCTCCATGGGGTCCGCGGCAAATATGCCTTGGCGCCTGTTGACAATTAATCATCGGCA LM56 
gD39_galK_r ATCGGGAGGCTGGGGGGCTGGAACGGGTCCGGTAGGCCCGCCTGGATGTGTCAGCACTGTCCTGCTCCTT LM56 
gD5_galK_f TTGTCGTCATAGTGGGCCTCCATGGGGTCCGCGGCAAATATGCCTTGGCGCCTGTTGACAATTAATCATCGGCA LM57 
gD44-39_11SG_galK_r AGGCCCGCCTGGATGTGGGATCCACCGGAACCAGAGCCACCGCCACTCGATCAGCACTGTCCTGCTCCTT LM57 
gB_852_galK_f CGGTAAACTGCATCGTCGAGGAGGTGGACGCGCGCTCGGTGTACCCGTACCCTGTTGACAATTAATCATCGGCA LM290 
gB_1648_galK_r TCGCCGAGCATCCGCGCGCTCACCCGCCGGCCCACGGTGGCCGAGGCGATTCAGCACTGTCCTGCTCCTT LM290 
 
 
Table 3.3.4  - Primers for knock out of galK cassette and insertion of the final construct. DNA templates for each primers  
pair were pEA99, which contains the wt gD coding sequence in pcDNA 3.1(-) (165); pSL1180-scFv-PSMA, pMR1-ENV1 and 
gB D285N A549T respectively. 
 
Primer name Sequence HSV-1 
BAC 
gDup_50mer_f TAAGCTTCAGCGCGAACGACCAACTACCCCGATCATCAGTTATCCTTAAG LM55 
gDdown_50mer_r TGTCCACCTTTCCCCCCTTCCAGACTCGCTTTATATGGAGTTAAGGTCCC LM55 
gD5_J591_f TTGTCGTCATAGTGGGCCTCCATGGGGTCCGCGGCAAATATGCCTTGGCGGAGGTGCAGCTGCAGCAGTCAGGACC LM593 
gD39_SG11_r ATCGGGAGGCTGGGGGGCTGGAACGGGTCCGGTAGGCCCGCCTGGATGTGGGATCCACCGGAACCAGAGCCACCGC LM593 
BAC_LM613_f TTGTCGTCATAGTGGGCCTCCATGGGGTCCGCGGCAAATATGCCTTGGCGCAGGTGAAACTGCAGCAGTCTGG LM613 
BAC_LM613_r AGGCCCGCCTGGATGTGGGATCCACCGGAACCAGAGCCACCGCCACTCGATTTGATTTCCAGCTTGGTGCCATCAC LM613 
gB_D285N_Eco93mer_f 
TACGGGACGACGGTAAACTGCATCGTCGAGGAGGTGGACGCGCGCTCGGTGTACCCGTACAACGAATTCGTGC
TGGC 
GACTGGCGACTTTGTG 
LM291 
gB_A549T_87mer_r 
GGCCATCACGTCGCCGAGCATCCGCGCGCTCACCCGCCGGCCCACGGTGGCCGAGGCGATGGTGTTGGGGTTC
AGCT 
TGCGGGCCTC 
LM291 
 
 
 
3.5 Reconstitution of viral progeny from BAC-DNA and virus cultivation 
 
Briefly, the BAC-DNA was extracted from SW102 strain with NucleoBond® PC100 (Macherey 
Nagel) and was quantified by means of Eppendorf Biophotometer. The BAC DNA was 
transfected into wt-gD-expressing and complementing RGDp6 cells (166); next, a single round 
of infection was performed in RS cells to remove any virus pseudotyped with wt-gD. Starting 
from seeds in RS, retargeted viruses were cultivated in cell lines expressing the heterologous 
receptors: R-LM249 and R-LM291 in SK-OV-3 cells, R-LM113 in J-HER2 cells, R-LM593 in J-
PSMA and R-LM613 in J-EGFRvIII and U251EGFRvIII . Infection was monitored by 
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observation of the cythopathic effect and EGFP fluorescence. Viral stocks were prepared from 
lysates of infected cells collected at low speed centrifugation (2000 rpm, 10ˈ). Extracellular 
virions were harvested from infected cell supernatants by ultracentrifugation with 45Ti rotor 
Beckman (14.000 rpm, 50ˈ). The titer of viral stocks and extracellular virion preparations was 
determined in SK-OV-3 (HER-2 retargeted viruses) or U251EGFRvIII cells monolayers, 
overlaid with 1% SeaPlaque Agarose (Lonza) in RPMI 1640 Glutamax-I, supplemented with 6% 
FBS. For virus retargeted to PSMA the titer was determined by TCID50 in J-PSMA cells 
overlaid as above mentioned. Viral stock and extracellular virions were stored  in aliquots at -80°C. 
 
3.6 Viral yield  assay  
 
Cells were seeded in replicate 12-well plates and were infected with different viruses (R-LM5, 
R-LM249, R-LM291 or R-LM613) at 1 or 0.1 pfu/cell for 90 min at 37°C. Non penetrated 
extracellular virus was inactivated by means of a pH3 wash (40 mM citric acid, 10 mM KCl, 135 
mM NaCl, pH3 (167)) Replicate cultures were frozen at 3, 24, or 48 h after infection, and the 
viral progeny (cell associated and supernatant) was titrated on SK-OV-3 cells for HER2 
recombinant viruses and U251EGFRvIII for R-LM613. R-LM5 was used as control and was 
titrated on the same cells of recombinant virus titration. 
 
 
3.7 Infection assay  
 
A number of cell lines in 96-well plates (~105 cell/well) were infected with recombinant viruses 
stocks (MOI 5). Infection was monitored as EGFP expression 24 or 48 h later. Digital pictures were 
taken with a Kodak camera connected to a Zeiss Axioplan fluorescence microscope. For fluorometer 
measurement, the infection was conducted in the same way, after 24 or 48 h plates were read at 
485/528 nm by Synergy HTTR-I fluorometer (Bio-TEK). 
 
3.8 Inhibition of virus infection 
 
SK-OV-3 cells grown in 96-well plates were exposed for 2 h on ice with increasing 
concentrations of antibodies (R1.302 against nectin-1, Herceptin against HER2, or mouse 
immunoglobulins) diluted in Dulbecco’s modified Eagle medium without serum and then with 
the viral inoculum at an MOI of 2 PFU/cell (as titrated in SKOV3 cells) for a further 90 min on 
ice. Following virus adsorption, the unattached virus was removed and the cells were washed 
twice with ice-cold RPMI Glutamax supplemented with 2.5% fetal bovine serum. The cells were 
overlaid with medium containing the 
same concentration of antibodies or immunoglobulin G (IgG), rapidly shifted to 37°C, and 
incubated for 16 h. Infection was quantified as the EGFP fluorescence intensity by means of a 
Victor plate reader (Perkin Elmer). The 100% value represented data obtained with cells infected 
with virus in the absence of antibodies. 
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3.9 In vitro cytotoxicity 
 
3.9.1 Erythrosin B assay 
 
Cells were seeded in 12-well plates, infected the next day after at 3 pfu/cell, or left uninfected. 
At different time points cells were trypsinized and collected, and the number of viable and 
nonviable cells was determined by means of the Erythrosin B (Sigma) dye exclusion assay. The 
number of viable cells (Erythrosin negative) in infected samples was expressed as percentage of 
viable cells versus the respective uninfected sample. 
 
3.9.2  Alamar Blue Assay 
 
Cells were seeded at 4x103 cells /well in 96 multiwell plates. For any virus tested three replicate 
plates were prepared. Next day, the replicate cultures were infected with escalating doses ranging 
from MOI 10 to 0,0032 of virus (R-LM291, R-LM613 or R-LM5). The Alamar Blue (10 ul/well, 
Life Technologies) was added to medium at 24, 48 or 72 hours post infection and incubate 4h at 
37°C. Then, plates were read at at 570 and 600 nm with a fluorometer.  
The cellular viability was expressed as percentage of difference in reduction of Alamar Blue 
between infected and uninfected cells, taking into account the fluorescence contribution of the 
medium. The following formula was used: 
 
[(εοx) λ2 Αλ1 − (εοx) λ1 Αλ2] −  [(εοx) λ2 Α∗λ1 − (εοx) λ1 Α∗λ2] 
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−   x 100 
 [(εοx) λ2 Α°λ1 − (εοx) λ1 Α°λ2] −  [(εοx) λ2 Α∗ λ1 − (εοx) λ1 Α∗λ2] 
 
where (εοx)λ2 = 117,216; (εοx)λ1 = 80,586; Α λ1 and Α λ2  are the absorbance for infected well at 
570 nm and 600 nm; Α°λ1 and Α°λ2 are the absorbance for uninfected cells at 570 nm and 600 
nm respectively; Α∗λ1 and Α∗λ2 are the absorbance of medium at 570 nm and 600 nm 
respectively. 
 
 
3.10 In vivo experiments 
 
3.10.1 Tumor growth  
Athymic Crl:CD1-Foxn1nu (referred to as nude) mice were purchased from Charles River, and 
maintained under sterile conditions. Experiments were authorized by the institutional review 
board of the University of Bologna, and were performed according to Italian and European 
guidelines. Groups of individually tagged virgin female nude mice of 6 weeks of age received 
the s.c. injection of a tumorigenic dose of SK-OV-3 cells (2*106 cells) or SJ-Rh4 cells (30*106 
cells) or BT-474 cells in 0.2 mL PBS. Tumor growth was assessed weekly by measuring with a 
caliper, tumor volume was calculated as pi[√ (a*b)]3/6,  where a is the maximal tumor diameter, 
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and b  the tumor diameter perpendicular to a. To perform cytofluorometric analysis, tumor 
samples, washed in PBS, were mechanically and enzymatically dissociated (0.5 mg/mL trypsin, 
0.2 mg/mL EDTA; Invitrogen) at 37 °C for 5 min. Cell suspension was filtered across a 70 m 
cell strainer (Falcon Plastics). 
 
 
3.10.2 In vivo infection.  
Mice with SK-OV-3 or SJ-RH4 s.c. tumors received an i.t. injection of R-LM249 in 0.2 ml PBS, 
and were killed 6, 48, and 72 h later. Resected tumors were cut in half and observed under a 
fluorescent in vivo imager (Lightools Research). Accurate observation of other organs did not 
reveal any fluorescence. 
 
3.10.3 Antitumor activity.  
At 3 days after tumor cell injection or at definite tumor volumes, mice were randomized in 
groups of 5–10, and R-LM249 injected in 0.2 ml PBS in tumor site or i.t. ‘‘No virus’’ control 
groups, run in parallel, consisted of mice untreated and treated with PBS only (not statistically 
different). Latency time corresponded to a tumor mass ≥ 0.03 cm3. Tumor volumes for each 
group and time were calculated as mean ±SE, until all mice of the group were alive. 
 
3.10.4 Statistical analysis.  
Tumor-free survival curves (Kaplan–Meier) were compared by the Mantel-Haenszel test. Tumor 
volumes were compared by the Student’s t test. 
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4. Results 
 
4.1 R-LM249 
 
 
 
4.1.1  Genetic engineering of  the recombinant HSV-1-BAC R-LM249  
Our goal was to generate a oncolytic HSV-1 that at the same time was retargeted to HER2 
receptor and detargeted from HSV-1 natural receptors (Nectin-1 and HVEM) through the genetic 
engineering of gD, the main determinant of HSV-1 tropism. The gD crystal structure showed a 
natural Ig-folded core (39-41) that was found to serve as a scaffold between the N-terminal and 
C-terminal of the gD ectodomain (37).  We replaced the Ig-folded core (aa 61-218) of gD with a 
scFv directed to HER2 (scHER2) (164): scHER2 sequence was flanked by a short Ser-Gly linker (8 
aa) at the N-terminus and a longer Ser-Gly linker (12 aa) at the C-terminus and gD had no mutations 
at N-terminus sequence. The chimeric gD was introduced in the HSV-1-BAC genome in place of wt 
gD by means of the two step replacement technique. Briefly, we created the shuttle vector pS249 
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containing the chimeric gD flanked by the its upstream and downstream sequences and we 
introduced it in a gD-EGFP-HSV-1-BAC that carries EGFP cassette inside BAC sequences 
between UL3-UL4 of HSV-1 (44). Fig.4.1.1 shows the linear map and the crystal structure of gD 
(Panel 4.4.1B), gD without its Ig-like folded core (gutless gD, Panel 4.4.1C) and the final construct 
of the protein with the superimposition of the scHER2 crystal (Panel 4.4.1D). 
 
 
 
Figure 4.1.15 - Linear and three-dimensional diagrams of gD in R-LM249. A) Linear map of gD that shows the scHER2 
insertion in deletion aa 61-218 of gD. The size of the scFv insert is drawn to scale. L linker, s.p signal peptide, VL and VH: 
variable light and heavy chains of scFv, TM transmembrane domain and ∆ deletion. B) Monomeric structure of gD ectodomain  
(PDB entry 2C6 (40)); color legend: red - gD N-terminus (aa 23-32), blue - C-terminus (aa 257-307), dashed blue line – 
unresolved residues, gray – gD deletion in R-LM249 (aa 61-218) and yellow as other portions. C) gD without aa 61-218. D) 
Structure of gD in R-LM249 with superimposition of scHER2 crystal (PDB entry 1N8Z) drawn to scale. The orientation of two 
crystals is arbitrary. For crystal graphic creation, visual molecular dynamics (VMD) software was used (168). 
 
 
4.1.2 R-LM249 is retargeted to HER2 receptor and detargeted from HSV-1 natural 
receptors 
 
We reconstituted R-LM249 virus in a gD complementing cell line (RGDp6) in order to promote 
the efficiency of particle assembly and virus spread. Psudotyped viruses carrying  wt-gD were 
removed by a single round of infection in RS cells. To evaluate the retargeting and detargeting of 
R-LM249, first we infected a pool of hamster cells transfected to express single receptors and 
several cell lines from human, murine, simian and rabbit origin. The parental J cells do not 
express any HSV-1 receptor unlike J-HER2 (expressing HER2 receptor) and therefore they are 
not susceptible to wt HSV-1 infection. J-Nectin1 and J-HVEM cells express Nectin-1 and 
HVEM receptors respectively and are infected by wt HSV-1 as all other cells tested. The viral 
infection was monitored as EGFP fluorescence (Fig. 4.1.2). R-LM249 infected at high levels 
only J-HER2 and SK-OV-3 cells and did not infect other cells of the pool except for RS and 
VERO cells where small and sparse plaques occurred. As control, we tried to grow the virus in 
these two cell lines and EGFP fluorescence and cytopathic effect were lost in few passages. 
Further to this, the virus was titrated on RS and VERO to quantify the degree of replication and 
the results  showed a range of titer of about 4-5 orders of magnitude lower than in cells 
permissive to infection as SK-OV-3 cells (data not shown).  
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Next, we performed the same infection assay measuring the EGFP fluorescence by a 
fluorometer. R-LM249 showed a high specificity for the heterologous receptor, infecting only 
HER2 positive cells i.e. J-HER2, SK-OV-3 (high expression) and MCF-7 mammary carcinoma 
cells (intermediate HER2 expression) (Fig. 4.1.3).  These results also demonstrated that R-
LM249 needs a high HER2 expression to infect efficiently cells. R-LM249 failed to infect HER2 
negative cells as SJ-Rh4 and cells positive for Nectin-1 and HVEM. 
 
 
 
Figure 4.1.16 - R-LM249 infects efficiently HER2 expressing cells. Cell lines were infected at MOI 5 and grown at 37°C for 
24 h. The infection was monitored by EGFP fluorescence. Digital pictures were taken with a Kodak camera connected to a Zeiss 
Axioplan fluorescence microscope. 
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Figure 4.1.17 - R-LM249 infection assay shows effective retargeting to HER2 receptor. Cell lines were infected with R-
LM249 and were monitored by EGFP fluorescence 24 hours post infection. Fluorescence emission was measured with a 
fluorometer (r.f.u. reltative fluorescence units).  The + and – in the bottom line refer to levels of HER2 expression (44).  
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Figure 4.1.18 - HER2 expression levels in different cell lines. The membrane HER-2 expression was evaluated in J, J-HER2, 
SJ-Rh4, MCF-7, MDA-MB-453, SK-BR-3 and SK-OV-3 cell lines by indirect immunofluorescence with mAb MGR-3 anti 
HER2 (red curve) or secondary antibody alone (empty curve). HER-2 median fluorescence intensities were: J, 4; J-HER-2, 407; 
SJ-Rh4, 4; MCF-7, 72; MDA-MB-453, 340; SK-BR-31241; and SK-OV-3, 1655. Cells were analyzed by FACScan flow 
cytometry (Becton Dickinson) (44). 
 
To confirm the first results about retargeting, viral yield of R-LM249 was compared with that of 
R-LM5, a HSV-1-BAC carrying EGFP gene within the BAC sequences and wt-gD (80). SK-OV-
3 and I143tk- cells, expressing HER2 or not respectively, were infected with two different 
multiplicities of infection (MOI) and frozen at 3, 24, 48, and 72 hours post infection. This virus 
replication assay supported and strengthened our preliminary results  of cell infections. The viral 
59 
 
titration showed that both viruses were able to grow efficiently in SK-OV-3 cells while R-
LM249 failed to replicate in I143tk- , exhibiting a titer of 6 logarithms lower than R-LM5 (Fig. 
4.1.5).  
 
 
 
Figure 4.1.19 - R-LM249 and R-LM5 viral yield in SK-OV-3 (HER2 positive) and I143tk- cells (HER2 negative). Cells 
were infected at 0.1 and 1 multiplicity of infection (MOI, pfu/cell) and harvested at 3, 24, 48, 72 h post infection. Samples were 
titrated in SK-OV-3 cells (44). 
  
 
4.1.3 R-LM249 is selective for HER2 receptor usage and cytotoxic to HER2 positive 
cells 
To evaluate the level of specificity through which R-LM249 enters the cells through the binding 
to HER2 receptor we performed an inhibition of virus infection assay. SK-OV-3 cells were 
infected with R-LM249 in presence of escalating doses of Herceptin, the humanized monoclonal 
antibody (mAb) to HER2 used in clinical therapy. As control, infection was measured in 
presence of mAb R1.302 to nectin-1 or unspecific mouse IgG. The inhibition curve showed that 
only Herceptin impaired R-LM249 infection in a dose dependent manner (Fig. 4.1.6A) while 
mAb R1.302 and mouse IgG did not exert any inhibitory effect.  
As further proof of R-LM249 specificity we measured its cytolytic activity compared with that 
of R-LM5 in number of cells expressing HER2 at different degrees. SK-OV-3, SK-BR-3 and 
MDA-MB-435 cells exhibit an high level of HER-2 expression (Fig. 4.1.4), whereas I-143tk-, 
HEp-2 and SJ-Rh4 cells do not. Cell lysis was estimated by the erithrosin dye exclusion test. R-
LM249 was cytotoxic for all HER-2 positive cells, and not cytotoxic for HER-2 negative cells. 
Conversely, R-LM5 was cytotoxic for all cells tested (Fig. 4.1.6B). 
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Figure 4.1.20 - The HER2 receptor usage of R-LM249 is specific. A) Inhibition of virus infection in presence of escalating 
doses of Herceptin to HER2, mAb R1.302 to nectin-1 or nonimmune mouse IgG. B) Cytotoxicity of R-LM249 and R-LM5 at 
MOI 3 for HER2 positive (i) or HER2 negative (ii) cells. Cell viability was measured by means of the Erythrosin exclusion assay 
(44). 
 
These first in vitro experiments established that R-LM249 was completely retargeted to HER2 
receptor and detargeted from HSV-1 natural receptors and also that the receptor recognition was 
highly specific and efficient to mediate a cytolytic activity. These results allowed us to move to 
in vivo experiments in mice. 
 
4.1.4 R-LM249 has a high safety profile and is able to replicate in vivo  
 
We tested the safety profile of R-LM249 compared with that of R-LM5, by determination of the 
LD50. Nude mice were intraperitoneally i.p. injected  with R-LM249 or R-LM5 doses ranging 
from 5x104 to 5x108 pfu/mouse. Mice were kept under examination for the following 21 days 
and then survivors were sacrificed. The results showed a high safety profile of R-LM249 that 
caused neither the death nor signs of toxicity of any mouse injected, even those receiving the 
viral highest dose (5x108 pfu).  R-LM5 had a pfu/LD50 of about 5x104  (Fig. 4.1.7A). To assess 
the ability of virus to replicate in vivo and to exhibit target specificity, R-LM249 was 
administered through intratumor injection (i.t.) in nude mice bearing subcutaneously HER2 
positive or negative tumor masses. After 48 hours post viral inoculation tumors were resected 
and cut to expose the inner parts. EGFP fluorescence was detected only in HER-2 positive tumor 
masses demonstrating the ability of virus to infect and spread only in presence of the desired 
target (Fig 4.1.7B). Indeed, the HER2 negative tumors did not show any sign of infection at any 
time. 
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Figure 4.1.7 - R-LM249 safety profile and replication in vivo. A) Kaplan-Meier survival curve of nude mice injected i.p. with 
R-LM249 or R-LM5. Five mice were injected for each dose. R-LM249 was injected also at 5x104 and 5x105 left all mice alive 
(not reported on the plot). B) EGFP fluorescence of HER2 positive (SK-OV-3 cells) and negative (SJ-Rh4 cells) tumor masses. 
Each tumor sample was obtained from 1 nude mouse at the indicated time after i.t. injection of R-LM249 at 2x107 pfu/mouse. 
The EGFP fluorescence was visualized under a fluorescent in vivo imager (44). 
 
4.1.5 R-LM249 is effective and specific in reducing tumor growth of subcutaneous 
ovarian tumor model  
 
SK-OV-3 cells share with a subset of human breast and ovarian cancer high levels of HER2 
receptor expression and the resistance to the mAb Herceptin. For these reasons, we chose this 
cell line to test the oncolytic activity of R-LM249 in vivo. These experiments were conducted in 
collaboration with Prof. Pier Luigi Lollini’s group at the University of Bologna. Nude mice were 
injected subcutaneously (s.c.) with SK-OV-3 cells and after 3 days they received in the same site 
a R-LM249 administration  ranging from 106 to 108 pfu/mouse. Treated mice showed an 
inhibition of the tumor growth at doses higher than 106 pfu with the result of  20% of tumor free 
mice in each group. The most effective doses was 2x107 pfu/mouse that strongly slowed tumor 
growth as showed by masses smaller than 0.3 cm3 in size for up to 2 months after tumor cell 
injections (Fig. 4.1.8A). Next, we injected the virus in tumor that had already reach a tumor 
volume of about 0,2 cm3. R-LM249 at 2x107 pfu/mouse was effective in reducing tumor masses 
that were maintained under 1 cm3 up to 2 months after tumor cell inoculation (Fig. 4.1.8B). 
Subcutaneous tumors observed 15 days after virus treatment showed a visible regression in 
volume (Fig. 4.1.8C). The experiment was also performed for tumor masses larger than 0.2 cm3 
with no sign of appreciable regression in size (data not shown). The specificity of R-LM249 was 
also demonstrated by results in mice inoculated with HER2 negative cells (SJ-Rh4) and treated 
with R-LM249. In these mice, the virus was not able to reduce the tumor mass at both doses 
tested (2x107 and 108 pfu/mouse) (Fig. 4.1.8D).  
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Figure 4.1.21 - Inhibition of tumor growth by R-LM249 in vivo. A) R-LM249 was injected at escalating doses in nude mice 
bearing progressive HER2 positive or negative tumors. Each point represents mean tumor volume ± SEM of 5 nude mice that 
received R-LM249 i.t. 3 days after the s.c. injection of SK-OV-3 cells. Statistical significance of difference vs control group “No 
virus” (Student’s t test): 106, not significant; 107 and 108, P< 0.05 from day 53; 2x107, P<0.01 from day 21. B) Each point 
represents mean tumor volume ± SEM of nude mice bearing a SK-OV-3 tumor treated i.t. with R-LM249. C) Mouse bearing a 
0.22 cm3 SK-OV-3 tumor (Left) was treated i.t. with 108 pfu R-LM249. (Right) Picture taken 15 days later. D) Kinetics of SJ-Rh4 
s.c. tumor appearance in groups of 5–10 nude mice treated with R-LM249 as in A. No significant difference vs. control group 
(“No virus”) (44). 
 
To assess the ability of R-LM249 to prolong tumor growth inhibition we performed repeated  i.t. 
administrations in nude mice with the most effective dose. Virus was injected at 3, 21, 39 and 63 
days after that mice received a subcutaneous inoculation of SK-OV-3 cells. The 2x107 pfu/mouse  
dose of R-LM249 exhibited a lengthening in the inhibition time of tumor growth. In particular, 
60% of mice were tumor free up to seven months after the last virus injection (Fig. 4.1.9A). 
Next, mice were sacrificed and the necroscopic examination did not discover tumor masses at 
low magnification under white light and at 488 nm (for EGFP expression). The 40% of mice that 
were not tumor free showed a tumor size under 1 cm3 up to at least 2 months after the last 
treatment (Fig. 4.1.9B). 
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Figure 4.1.22 - R-LM249 oncolytic activity after repeated injections. Groups of 5 nude mice received the s.c. inoculation of 
HER-2-positive SK-OV-3 cells and were treated with repeated i.t. injections of R-LM249 at days 3, 21, 39, and 63 (red arrows). 
A) Kaplan–Meier analysis of tumor free survival time. Tumor-free survival of R-LM249-treated mice was significantly different 
from that of control group (“No virus”) (P < 0.005 by the Mantel-Haenszel test). B) Tumor growth curves, each point represents 
mean tumor volume ± SEM of 5 nude mice (including tumor-negative mice). All time points after day 18 were significantly 
different (P < 0.01 by the Student’s t test) (44). 
 
 
4.1.6 R-LM249 is effective and specific in reducing tumor growth of subcutaneous 
mammary tumor model  
 
As already shown, BT-474 cells express high level of HER2 receptor (Fig. 4.1.4), and are 
generally used as model for breast carcinoma (169). After the promising results in a 
subcutaneous model of ovarian cancer we switched to a subcutaneous mammary tumor model 
and repeated intratumoral administrations of two doses of R-LM249. The model consisted of 
nude mice bearing HER2 positive tumors from BT-474 cell line. In Fig. 10A  black arrows 
indicate virus administrations. The result was an inhibition in the growth of human mammary 
tumors. In particular, 60% of mice were tumor free after approximately 80 days from cells 
inoculation (Fig. 4.1.10 B), while the remaining 40% showed the size of the tumor drastically 
reduced (Fig. 4.1.10A). For this experiment, the most effective dose was 108 pfu/mouse unlike 
the ovarian model where it was 2x107pfu/mouse.  
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Figure 4.1.23 - Antitumor efficacy of R-LM249 in BT-474 subcutaneous mammary tumor model. Nude mice s.c. inoculated 
with BT-474 cells, were injected i.t. with 2x107 and 1x108 pfu/mouse of R-LM249 in ten repeated administration. A) Tumor 
growth curve, each point represents mean tumor volume + SEM.  B) Kaplan – Meier survival curve for BT-474 tumor masses 
treated with R-LM249 compared to control mice (PBS).   
 
 
4.2 R-LM113 
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4.2.1 R-LM113 is safe in NOD/SCID mice 
 
R-LM113 is a replication competent HSV-1-BAC fully retargeted to the human HER2 receptor 
and detargeted from natural HSV-1 receptors (80). The viral tropism was modified through the 
insertion of the scHER2 in place of amino acids 6-38 deletion in virion envelope glycoprotein 
gD. The deletion eliminated residues involved in HVEM binding and one of the residues (aa 38) 
involved in Netin-1 binding. Moreover the size of the heterologous insert was able to mask 
residues responsible of  Nectin-1 recognition (80). Because the HER2 receptor is highly 
expressed in some forms of glioblastoma, we used this virus in a orthotopic mouse model of this 
malignant brain tumor. The experiments were performed in NOD/SCID mice strain highly 
sensitive to HSV-1 infection in collaboration with the group of Dr. Paolo Malatesta (IST-Genoa). 
First of all, we assessed the safety profile of R-LM113 compared with that of R-LM5. Both 
viruses carry EGFP as reporter gene inserted into the  BAC sequences.  
Five mice were injected intracranially with 3x105  pfu/mouse of R-LM113. As control the same 
number of mice received 105 pfu/mice of R-LM5. The R-LM113 dose administered was the 
maximum allowed by the small volumes that can be injected intracranially (i.c.). All mice 
inoculated with R-LM5 died for lethal encephalitis between 7 to 10 days after viral injection and 
the explanted brains showed large EGFP positive areas (Fig. 4.2.1 a,b,c). The same brains were 
sectioned and stained with haematoxylin and eosin and showed an extensive extravasation (Fig.  
4.2.1 d). Furthermore the sections resulted positive to granulocytes and macrophages markers by 
means of myeloperoxidase (MPO) and F4/80 staining to indicate their massive infiltration (Fig. 
4.2.1  e). Conversely, mice treated with R-LM113 did not die and were sacrificed 7, 12 and 25 
days after virus administration to control the presence of viral spread and neuroinvasiveness. 
Mice showed neither any sign of EGFP fluorescence nor of extravasation (Fig. 4.2.1 f-i). 
Moreover there was not macrophages  and granulocytes infiltration (Fig. 4.2.1 j). The results 
indicate that R-LM113 is safe because it is not able to infect normal brain tissue, whereas R-
LM5 is lethal even at lower doses than that used for our recombinant virus. 
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Figure 4.2.1 - R-LM113 in safe in vivo. NOD/SCID mouse brains were explanted after injection of 105 pfu/mouse of R-LM5 (a-
c) or 3x105 pfu/mouse of R-LM113 (f-h) and observed in merged fluorescence and brightfield. Viral spread is visualized by 
EGFP fluorescence. Coronal section of adult NOD/SCID mouse brains after injection of R-LM5 (d,e) or R-LM113 (i,j) stained 
with heamatoxylin and eosin (d,i) or with antibody for the indicated markers (e,j). Extravasation area areas (empty arrowheads in 
d), infiltration of granulocytes (arrowheads in e) and macrophages (arrow in e) in the parenchyma are present in R-LM5 injected 
brains. Conversely, granulocytes are exclusively found inside blood vessels of R-LM113 injected brains (arrowheads in j). Scale 
bars 20 µm. 
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4.2.2 Generation of an in vivo high grade glioma model expressing HER2 
 
To test R-LM113 oncolytic activity in high grade glioma in vivo, we needed to generate a glioma 
model expressing the HER2 receptor. Murine gliomas cells (mGBM), derived from PDGF-B 
induced murine gliomas, are able to develop secondary tumors after their orthotopic 
transplantation in adult mice and emit red fluorescence because they carry and express a 
transgenic DsRed protein (170, 171). mGBM cells were stably transfected with a plasmid 
carrying the coding sequence of HER2 receptor. The presence of heterologous receptor in 
membrane was assessed by indirect immunofluorescence (IFA)  (Fig. 4.2.2 a,e ). We did not 
know if the presence of HER2 could impair mGBM cells phenotype or their ability to develop 
high grade glioma tumors. For this reason mGBM-HER2 and the parental cell line mGBM were 
stained with several typical gliomas markers in an immunocytochemical analysis (Fig 4.2.2 
b,c,d-f,g,h ). The results confirmed that the HER2 transfection did not compromise the mGBM 
cellular profile. In particular we took into account staining for Ng2 (chondroitin sulfate 
proteoglycan) as a marker of oligodendrocytes; Nestin, a intermediate filament protein express in 
nerve cells for radial growth of the axons and Oligo2, that is a marker of oligodendrocytes 
development. Next, mGBM-HER2 cells were transplanted intracranially in adult NOD/SCID 
mice for the evaluation of their tumorigenic potential. The brains explanted, after two months, 
showed a broad red fluorescent area (Fig. 4.2.2 k) corresponding to the tumor mass, that had a 
rather compact structure and wide necrotic areas surrounded by highly proliferating cells 
forming pseudopalisades. The staining with haematoxylin and eosin as well as MPO and F4/80 
revealed signs of extravasation and lymphocytes infiltration (Fig. 4.2.2 i). All results confirmed 
that the HER2 transfection in mGBM cells did not affect their cellular and tumorigenic 
properties. 
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Figure 4.2.2 - mGBM-HER2 cells did not change their biological and tumorigenic potential after HER2 stable 
transfection. (a-d) Immunostaining of mGMB (a-d) and mGBM-HER2 (e-h) with the markers indicated on each picture. (j) 
Merged fluorescence and brightfield images in dorsal view of a brain explanted from a mouse injected intracranially with 
mGBM-HER2. The tumor mass is visible as DsRed fluorescence. (k,l) Haematoxylin and eosin staining of coronal section of 
tumors derived by mGBM-HER2 cells; dashed lines trace the pseudopalisade boundaries while arrows highlighted the 
extravasation area. (n-u) Immunostaining of coronal section of tumors derived by mGBM-HER2 cells. The antibody used are 
indicated on each pictures (green). Arrows indicate macrophages in n, arrowheads indicate granulocytes in n, o. Ds-Red 
fluorescence is visible in p-u. Nuclei are counterstained in blue with Hoechst 33342 in a-h, n-u. Scale bar, 15 µm (a,e); 25 µm (b-
d,f-h,k); 12 mm (j); 40 µm (l,) . 
 
4.2.3 R-LM113 infects and spreads in  mGBM-HER2  
 
Once it was established that the mGBM-HER2 cells were biologically identical to parental 
mGBM, we verified that  they were susceptible and permissive to R-LM113 infection. Replicate 
cultures of mGBM-HER2 and mGBM cells were exposed to serial dilutions of R-LM113 or R-
LM5 as control. The infection was detected after 24h as EGFP fluorescence (Fig. 4.2.3 a-d and 
aˈ-dˈ). In another experiment the efficiency of infection of R-LM113 in mGBM-HER2 was 
quantified respect to that of R-LM5 with a  fluorometer. Two replicas of cells were infected at 
the same MOI with the two viruses (titrated on SK-OV-3 cells). R-LM113 infected about 11±3% 
of mGBM-HER2 cells while R-LM5 infected about 71±3% of cells (Fig. 4.2.3  e,f).  
R-LM113 was also able of cell-to-cell spread in mGBM-HER2 cells as indicated in Fig.4.2.3 
(g,h,i). Cells were infected at low MOI (0.025 pfu/cell) and monitored over time for plaques 
formation.   
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Figure 4.2.3 - Infection efficiency and spread of R-LM113 in mGBM-HER2 cells. (a-dˈ) Pictures of mGBM-HER2 
(a,b,aˈ,bˈ) and mGBM (c,d,cˈ,dˈ) cells infected with R-LM113 (a,c) and R-LM5 (b,d). Micrographs were taken in  brightfields 
(a-d) and EGFP fluorescence (aˈ-dˈ). (e-f) Representative dot plots of mGBM-HER2 cells infected with R-LM113 and R-LM5 at 
MOI 5. The percentage of infected cells as EGFP fluorescence is reported on the graph and was evaluated through Image J 
analysis for the measurements of plot area and fluorescence intensity for each cell. The lines represents the threshold used. (g-i) 
Cell-to-cell spread of R-LM113 in mGBM-HER2 cells infected at MOI 0,025 and monitored for 72 h. Scale bar, 50 µm. 
 
4.2.4 Oncolytic activity of R-LM113 in vivo 
 
To evaluate R-LM113 oncolytic potential in vivo we performed two series of experiments that 
differed for the time of a administration: I) in the early treatment,  a mixture of non-infected and 
R-LM113 infected mGBM-HER2 cells was inoculated i.c.; II) in the late treatment the virus was 
injected when the tumor was already developed in the brain. The latter experimental scheme 
would like to mimic as close as possible the therapeutic application of an oncolytic virus. 
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Early treatment: for this experiment a pool of 24 NOD/SCID mice were enrolled and in three 
independent sessions, mice were inoculated intracranially with 2x104 mGBM-HER2 cells. In 
particular, at the same time of uninfected cells inoculation, 12 mice (herein referred to as “R-
LM113 early treatment set”) were injected also with 2x104 mGBM-HER2 cell previously 
infected in vitro with R-LM113. The other 12 mice  were used as control (“early-treatment 
control set”). Mice were monitored for 160 days. 
 
The results showed that mice belonging to “R-LM113 early-treatment set” had a significant 
lengthening in median survival time compared to controls (119 days vs 55 days respectively, log 
–rank test p< 10-4) (Fig. 4.2.4 a). All control animals showed neurological symptoms within 69 
days and their brain emitted DsRed fluorescence for presence of tumor masses (Fig. 4.2.4 b). 
Conversely, in the R-LM113 early treatment set, only two mice exhibited neurological 
symptoms caused by tumor masses. Three mice of the treated set group were sacrificed 66 days 
after cells transplantation in order to verify the virus infection. No detectable fluorescence was 
identified at a first macroscopic analysis while, after sectioning, the histological staining showed 
small cellularized areas with signs of sparse EGFP fluorescent cells as marker of active R-
LM113 infection (Fig. 4.2.4 c).  
Treated mice that developed neurological symptoms from 69 and 160 days after cells injections 
(n=5) were analyzed and their brains showed the presence of large DsRed tumor masses, two of 
which showed EGFP positive areas (Fig. 4.2.5 a ).  
Two animals of the R-LM113 early treatment set survived until the end of experiment without 
developing any neurological symptoms. One of them carried a DsRed positive tumor without 
signs of  EGFP fluorescence (Fig 4.2.5 b.bˈ). The tumor mass was still expressing HER2 
suggesting that the virus did not select for HER2 negative tumor cells (Fig. 4.2.5 c). The other 
mouse bore a very small region of DsRed and EGFP positive cells indicating that R-LM113 was 
actively hindered tumor growth (Fig. 4.2.5 d-dˈ). 
In conclusion the results evidenced that R-LM113 was able to infect, spread and destroy tumor 
cells in vivo, doubling  the median survival time of the treatment set compared to control. 
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Figure 4.2.4 - R-LM113 counteracts the growth of HER2-expressing gliomas. a) Kaplan-Meier plot for animals transplanted 
with mGBM-HER2 cells alone (red line, Early treatment control set) or together with R-LM113 infected mGBM-HER2 (green 
line, R-LM113 earlytreatment set). The crosses indicate mice censored for subsequent analysis. b) Merged DsRed fluorescence 
and brightfield image of a brain from a mouse of the control set (arrowhead labeled as b*in a). c) Coronal section of the brain 
from a mouse of the R-LM113 early-treatment set censored 66 days post-transplant (arrowhead labeled as c* in a); in green is 
shown EGFP expressed from the virus, 23 in blue the nuclei.  
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Figure 4.2.5 - R-LM113 counteracts the growth of HER2 expressing gliomas. a) Merged red and green fluorescence and 
brightfield images of the brain from a mouse of the R-LM113 early-treatment set which displayed neurological symptoms 120 
days after transplant. To note, the presence of a large DsRed tumor scattered of EGFP-positive areas. b,b') Matched fluorescence 
micrographs of a brain (outlined with dashed line) explanted from a mouse of the early treatment set sacrificed in absence of any 
neurologic symptom at the end of the planned observation period. To note the presence of a DsRed positive tumor mass (b) 
lacking any detectable EGFP fluorescence (b'). c) Immunofluorescence staining for HER2 of cells dissociated from the tumor 
represented in B-B'. OB: olfactory bulb. Scale bar: 1mm in a, 0.5mm in b, 40µm in c. d) Merged red and green fluorescence and 
brightfield images of the brain from a mouse of the R-LM113 early-treatment set censored 161 days post-transplant (arrowhead 
labeled as d* in a). d') Coronal section of the brain shown in d, along the dashed line. 
 
 
Late treatment: 2x104 mGBM-HER2 cells were intracranially inoculated in 28 NOD/SCID mice 
and after 45 days R-LM113 or UV-inactivated R-LM113, as control, were injected in the same 
stereotaxic coordinates in 20 mice and 8 mice respectively. The time elapsed between two 
inoculations (cells and virus) was chose because it was 10 days before the median survival time 
of early control set of the previous experiment. Only mice surviving at least 5 days after virus 
injection were considered, because the virus had time to replicate and spread and mice had time 
to recover from intracranial injection. 
Mice  treated  with the virus were called “R-LM113 late treatment set” while control mice were 
called “UV-R-LM113 late treatment control set”. 
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The results showed that mice belonging to “R-LM113 late-treatment set” had a significant 
lengthening in median survival time compared to controls (21 days vs 10 days respectively, 
p<0,003) (Fig. 4.2.6 a). The first three mice of the treatment set  with neurological symptoms had 
large DsRed tumor masses scattered with EGFP fluorescence indicating that the virus spread 
inside the tumor (Fig. 4.2.6 b). Likely these gliomas were already too advanced for effective 
treatment with the virus. 
The mouse that survived longer in the late treatment set died 37 days after virus injection. The 
brain revealed a small Ds-Red tumor mass scattered by EGFP-positive cells (Fig. 4.2.6 c). 
In order to assess the viral spread just after R-LM113 injection, the virus was administered to 
four additional mice which were sacrificed five days after, although they did not show any sign 
of neurological symptoms. In brains explanted, DsRed tumors scattered by EGFP fluorescence 
were present. Noteworthy, EGFP fluorescent cells were found in a site distant from which of 
injection, highlighting the ability of virus to spread into the tumor (Fig. 4.2.6 d). 
 
 
 
 
Figure 4.2.6 – R-LM113 R-LM113 improves mouse survival when injected in already established HER2-expressing 
gliomas. a) Kaplan-Meier plot for mice bearing mGBM-HER2 tumors inoculated with R-LM113 (green line) or with UV-
inactivated R-LM113 (red line). (b, c) Merged red and green fluorescence and brightfield images of brains from mice of the R-
LM113 late-treatment set died at 6 days (b, arrowhead labeled as b* in panel a) and at 37 days (c, arrowhead labeled as c* in 
panel a) following R-LM113 inoculation. d) Coronal section of a mGBM-HER2-bearing mouse injected with R-LM113 and  
sacrificed 5 days post inoculation. In green is shown the virally-expressed EGFP, in red the endogenous fluorescence of DsRed 
expressed by mGBM-HER2, in blue the nuclei. The right inset shows a magnification of the region distant approximately 1.3mm. 
AON accessory olfactory nucleus, CTX, cortex; rf, rinal fissure.  
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4.3 R-LM291 
 
 
 
 
Glorioso and coworkers reported that HSV expressing a mutant gD whose binding to wt Nectin-
1 was severely impaired developed two spontaneous compensatory mutations in gB (D285N-
A549T) when it was forced to enter in cells carrying a mutant form of Nectin-1 (56). The 
hyperactive gB, as it has been named by the authors, was found to increase the rate of entry of 
the virus even in the absence of receptors for authentic gD or compensate for inefficient gD-
receptor interaction. R-LM249 showed promising results in our in vivo experiments. Considering 
that mutations D285N-A549T in gB could increase both virus ability to spread from cell to cell 
and its oncolytic activity we decided to introduce mutations in gB described by Uchida in R-
LM249 genome through galk recombineering technology. The resulting virus was named R-
LM291 (Fig. 4.3.1). 
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Figure 4.3.1 – Schematic diagram of R-LM291 backbone. The viral HSV-1-BAC backbone is the same of R-LM249 in Fig.1, 
except for the two mutations in gB (light violet) D285N and A549T (asterisks). 
 
 
First, we inserted galK cassette between nucleotide 852 and 1648 of gB of R-LM249, generating 
R-LM290 (Fig 3.3.5 in material and methods). Next, we performed the gB mutagenesis with four 
mutagenic primers in a plasmid carrying the wt gB coding sequence. The insert was amplified by 
PCR using the mutated plasmid as template and it was electroporated in galK positive clone of 
R-LM290. Bacterial colonies carrying  R-LM291 were screened by colony PCR and the virus 
was reconsituted through transfection in SK-OV-3 cells. 
 
4.3.1 R-LM291 infects HER2 positive cells and spreads more efficiently in murine 
cells. 
 
In order to verify that R-LM291 maintained the retargeted tropism towards HER2-positive cells 
maintenance we performed an infection assay in several cells lines expressing HER2 receptor or 
cells lines expressing HSV-1 natural receptors. The infection was monitored as EGFP 
fluorescence at 48 h post infection. The results showed that R-LM291 was still able to recognize 
HER2 as the sole receptor for entry in cells. Indeed, it infected efficiently only HER2 positive 
cells i.e. J-HER2, SK-OV-3 cells. In micrographs of VERO and RS infected cells we noted an 
increase in fluorescence compared to R-LM249 infection assay (Fig. 4.3.2). The results observed  
in VERO and RS cells may derive from an acquired ability of R-LM291 to enter through a 
broader receptor spectrum as reported by Glorioso and coworkers (56). However, the virus was 
not able to grow in VERO or RS cells, loosing EGFP fluorescence and cytopatic effect in few 
passages. The titration in these cells confirmed  titers 4 logs lower than in SK-OV-3 cells. 
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Figure 4.3.2 - R-LM291 infects efficiently HER2 expressing cells. Cell lines were infected at MOI 3 and grown at 37°C for 24 
h. The infection was monitored by EGFP fluorescence. Digital pictures were taken with a Kodak camera connected to a Zeiss 
Axioplan fluorescence microscope. 
 
 
 
 
EGFP fluorescence emission by infected cells was quantified by a fluorometer. The results 
confirmed the first analysis based on cell infection. J-HER2 and SK-OV-3 were infected 
efficiently by the virus and VERO and RS cells gave a EGFP signal of detection different from 
R-LM249 (Fig. 4.1.3 and 4.3.3). 
77 
 
 
 
Figure 4.3.3 – R-LM291 infects HER2 positive cells. Cell lines were infected with R-LM291 and monitored by EGFP 
fluorescence 24 h post infection. The fluorescence value of the medium was subtracted from the infected or uninfected cells 
values. Fluorescence emission was measured with a fluorometer (r.f.u., relative fluorescence units).  
 
The mutation in gB conferred to R-LM291 the ability to spread more efficiently in murine cells 
compared to R-LM249. We infected at low MOI three murine mammary cells lines expressing 
HER2: 1E-huHER2, D2F2/E2-HER2 and FVB 6443.0 explanted from a tumor of a FVB/N 
HER-2/neu transgenic mouse (Genentech) with R-LM291, R-LM249 and R-LM5 as control.  
Cells were monitored up to 72 hours post infection through EGFP fluorescence detection. SK-
OV-3 cells were infected as control. R-LM291 showed large plaques already at 48 hours of 
infection in all murine cells tested (Fig 4.3.4). As expected, R-LM5 infected efficiently all cell 
lines that are susceptible to HSV-1 infection. R-LM249 infected slowly with plaques of small 
dimension.   
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Figure 4.3.4 – R-LM291 infected more efficiently murine cells than R-LM249. Cells were infected with low MOI of R-LM5, 
R-LM249 and R-LM291. The infection was monitored by EGFP fluorescence over the time (48h and 72h post infection). Digital 
pictures were taken with a Kodak camera connected to a Zeiss Axioplan fluorescence microscope. 
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4.3.2 R-LM291 exerts the same cytolytic activity and viral replication as R-LM249 
in HER2 positive cells. 
 
Our goal in generating R-LM291 was to increase its oncolytic activity as compared to the 
parental virus R-LM249. To verify this aspect, we measured R-LM291 cytolytic activity in SJ-
Rh4 and SK-OV-3 cells. The latter exhibits high level of HER-2 expression. Cell toxicity was 
measured over time by the Alamar Blue assay  and compared to that of R-LM5 and R-LM249 
(Fig. 4.3.5). All three viruses were cytotoxic to SK-OV-3 cells, leaving only 35% of viable cells 
at highest MOI, at 6 days post infection (Fig. 4.3.5 A). As expected, R-LM249 and R-LM291 
exhibited no cytotoxic activity at any doses tested in SJ-Rh4 cells whereas R-LM5 was able to 
kill 65% of cells 6 days post infection (Fig. 4.3.5 B).  
 
 
Figure 4.3.5 – R-LM291 and R-LM249 exerted the same cytotoxic activity only in HER2 positive cells. Cytotoxicity of R-
LM5, R-LM249 and R-LM291 in HER2 positive (SK-OV-3) (A) or HER2 negative (SJ-Rh4) cells (B). Cell viability was 
measured by means of the Alamar blue exclusion assay. Cells were seeded in replicated 96 multiwell plates and infected at the 
MOI indicated in the x axis. Every two days cells were assayed for reduction of resazurin to the fluorescent molecule, resorufin 
and we reported the reading at 6 days post infection. The absorbance was measure at 570/600 nm with a fluorometer. 
 
 
In addition, we assessed the difference between R-LM291 replication ability compared to that of 
R-LM249. Thus, we performed a viral yield assay comparing R-LM249, R-LM291 and R-LM5 
as control. SK-OV-3 cells and SJ-Rh4 cells were infected at MOI 1 with each virus. The titration 
was performed in SK-OV-3 cells on samples harvested 3, 24, 48 and 72 h post infection.  
The results showed that R-LM291 titration curve was identical to that of R-LM249. Both viruses 
replicated only in SK-OV-3 cells and failed to replicate in SJ-Rh4 cells (Fig. 4.3.6). As expected, 
the control virus R-LM5 replicated efficiently in both cell lines tested.  
 
80 
 
 
Figure 4.3.6 – R-LM291, R-LM249 and R-LM5 viral yield in SK-OV-3 (HER2 positive) and SJ-Rh4 (HER2 negative) 
cells. Cells were infected at 1 multiplicity of infection (MOI, pfu/cell) and harvested at 3, 24, 48, 72 h post infection. Samples 
were titrated in SK-OV-3 cells. 
 
4.4 o-HSV  retargeted to additional tumor specific receptors (PSMA and 
EGFRvIII) 
 
 
 
 
 
So far, the focus of my work was viruses retargeted to HER2 receptor. The results proved that the 
retargeting strategy was effective to drive the recombinant HSV-1, modified with the insertion of 
a scFv antibody, towards a specific heterologous receptor in vitro and on tumor model in vivo. 
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Hence, we took into account additional targets. In particular, we focused on the prostate specific 
membrane antigen (PSMA) and epidermal growth factor receptor variant III (EGFRvIII) which, 
as already reported in the introduction, are overexpressed in prostate carcinoma and glioma 
multiforme, respectively.  
Standard therapies demonstrated to be not sufficient for the eradication of these tumors. In 
particular, prostate cancer treatments place the patients at risk for temporary or permanent 
impotence, especially those patients who have undergone prostate surgery and radiation therapy. 
Patients affected by glioma have a median survival time from diagnosis of one year and these 
statistics have not changed in the past 50 years. Hence, the need to search new and novel 
therapies is very high.  
ScFv antibodies are available for both receptors making the  two targets suitable for the 
generation of new recombinant o-HSVs. 
 
As a first attempt, we introduced the scFv to PSMA and EGFRvIII in the N-terminal position of 
gD with galK recombineering technology. The resulting viruses were called R-LM593 and R-
LM613 (Fig. 4.4.1 A and B ). As in R-LM113 the scFvs were followed by a 11 serine glycine 
linker at C-terminal that was introduced during the recombineering procedures. 
 
 
 
 
Figure 4.4.1 – A-B  Linear maps of R-LM593 and R-LM613  Both scFv were inserted in the deletion of aa6-38 of gD by 
means of galk recombineering technology. VL and VH: variable light and heavy chains of scFv. 
 
4.4.1 R-LM593 and R-LM613 are retargeted to PSMA and EGFRvIII, respectively 
 
As for the other retargeted viruses described so far, first we verified the retargeting to 
heterologous receptors and the detargeting from HSV-1 natural receptors. We infected several 
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cells lines (hamster, human, simian and rabbit) monitoring the infection as EGFP fluorescence.  
 
R-LM593 was able to infect J-PSMA cells, that express PSMA and no HSV-1 natural receptor, 
and LNCaP cells derived from a metastasis of human prostate carcinoma expressing  PSMA at 
high levels and susceptible of wt HSV-1 infection (Fig. 4.4.2). The virus tropism resulted very 
specific as it infected only PSMA positive cells and did not infect any cell devoid of  HSV-1 
receptors as J cells or expressing HSV natural receptor J-nectin-1 H-HVEM, I-143-tk- and 293T 
cells. This indicated that the detargeting/retargeting was effective. However, we found small and 
sparse plaques in RS and VERO cells. This was a common feature of all our retargeted virus (see 
also R-LM249 and RLM-291). The plaques remained small in size and the virus cultivated on 
these cells was lost in few passages.  
 
 
 
 
 
Figure 4.4.2  - R-LM593 infects only PSMA expressing cells. Cell lines were infected at MOI 3 and grown at 37°C for 24 h. 
The infection was monitored by EGFP fluorescence at 24 h post infection. Digital pictures were taken with a Kodak camera 
connected to a Zeiss Axioplan fluorescence microscope. 
 
 
R-LM613 only infected cells expressing EGFRvIII as J-EGFRvIII and U251EGFRvIII, proving 
that its tropism has been redirected to the receptor target (Fig. 4.4.3). In addition, the virus was 
detargeted from HSV-1 natural receptors as evidenced by the absence of positive-fluorescent 
cells in J, J-Nectin-1, J-HVEM, I-143-tk- and 293T cells. Noteworthy, the virus did not infect J-
EGFR, expressing the wt form of the receptor. This result indicated that the scFv EGFRvIII 
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allows to discriminate between the native form of the receptor and the mutant one. Also in this 
case RS and VERO gave a background infection. 
 
 
 
Figure 4.4.3 - R-LM613 infects only EGFRvIII expressing cells. Cell lines were infected at MOI 3 and grown at 37°C for 24 
h. The infection was monitored by EGFP fluorescence at 24 h post infection. Digital pictures were taken with a Kodak camera 
connected to a Zeiss Axioplan fluorescence microscope. 
 
 
 
The results of infection assays were confirmed for both viruses by fluorometer reading of the 
EGFP signal in infected cells (Fig. 4.4.4 A and B).  
 
 
Figure 4.4.4 – R-LM593 and R-LM613 infect only cell expressing their target receptors.  A) R-LM593 infection. B) R-
LM613 infection. Cell lines were infected with R-LM593 or R-LM613 and monitored by EGFP fluorescence 48 h post infection. 
The fluorescence value of the medium was subtracted from the infected or uninfected cells values. Fluorescence emission was 
measured with a fluorometer (r.f.u., relative fluorescence units).  
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4.4.2 R-LM593 and R-LM613 specifically kill  the cells expressing the targeted 
receptors 
 
To assess ability of the recombinant viruses to kill cells expressing the target receptors and to 
further strengthen evidence for their specificity, we measured R-LM593 and R-LM613 
cytotoxicity by means of Alamar Blue assay. For R-LM593 the assay was performed with 
escalating MOI in four cell lines: two were PSMA positive (LNCaP and J-PSMA) and two were  
PSMA negative (J-nectin1 and SJ-Rh4). R-LM5 was used as control in the same cell lines. R-
LM593 was cytotoxic only in LNCaP and J-PSMA cells, lowering, at the highest doses, the 
percentage of viable cells to about 40% in 6 days for LNCaP cells and 60% in 4 days for J-
PSMA (Fig 4.4.5 A,C). By contrast, R-LM593 did not exert a cytotoxic activity in PSMA 
negative cells after 6 day for SJ-Rh4 and 4 days for J-Nectin1 (Fig 4.4.5 B,D). J nectin-1 cells 
showed a recovery of viability when infected with R-LM5 at low MOI. This was due likely to a 
small pool of J-Nectin1 cells that became resistant to the HSV infection and started to replicate. 
The results further demonstrated that R-LM593 was effectively retargeted to PSMA receptor and 
detargeted forma HSV-1 natural receptors. R-LM5 as expected was cytotoxic in all cell lines 
except for cells not expressing  HSV-1 receptor  i.e. J-PSMA. 
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Figure 4.4.5 - R-LM593 is cytotoxic for cell lines expressing PSMA. Cytotoxicity of R-LM5 and R-LM593 was tested in 
PSMA positive (A,C - LNCaP, J-PSMA) or PSMA negative (B,D J-nectin-1,SJ-Rh4) cells. Cell viability was measured by means 
of the Alamar blue exclusion assay. Cells were seeded in replicated 96 multiwell plates and infected at the MOI indicated in the x 
axis. Every two days cells were assayed for reduction of resazurin to the fluorescent molecule resorufin. We reported the reading 
at 6 days post infection. The reduction in  J-PSMA and J-nectin1 was measured until 4 days after infection because they died 
completely at day 6.  The absorbance was measured at 570/600 nm with a fluorometer.  
 
 
The cytotoxic activity of R-LM613 was assessed in two glioblastoma cell lines: U251EGFRvIII 
that express the target receptor EGFRvIII and the U251 that does not express EGFRvIII. Both 
cell lines were permissive and susceptible to wt HSV-1 infection. The results showed that R-
LM613 did not exhibit any cytotoxic activity in U251 (Fig. 4.4.6 A) while it was highly 
cytotoxic for U251 EGFRvIII cells carrying the cell viability to 40 % at the highest dose (MOI 
10) in 6 days (Fig. 4.4.6 B). The control virus R-LM5, as expected,  was cytotoxic for both cell 
lines.  
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Figure 4.4.6 - R-LM613 is cytotoxic only in EGFRvIII expressing cells. Cytotoxicity of R-LM5 and R-LM613 was tested in 
EGFRvIII negative (A- U251) or EGFRvIII positive (B - U251EGFRvIII) cells. Cell viability was measured by means of the 
Alamar blue exclusion assay. Cells were seeded in replicated 96 multiwell plates and infected at  escalating MOI. Every two days 
cells were assayed for reduction of resazurin to the fluorescent molecule, resorufin. The absorbance was measure at 570/600 nm 
with a fluorometer.  
 
 
4.4.3 R-LM613 grows efficiently in U251EGFRvIII and J-EGFRvIII cell 
 
To further validate our results about R-LM613 we carried out a virus yield assay infecting  
EGFRvIII positive cell lines i.e. U251EGFRvIII and J-EGFRvIII, or cells negative for the same 
receptor but expressing HSV-1 natural receptors J, J-Nectin-1, JHVEM and U251. The same 
cells were infected with R-LM5 as control. R-LM613 replicated efficiently in U251EGFRvIII 
and J-EGFRvIII indicating that it was able to recognize the target receptor in a specific fashion. 
Conversely, the R-LM613 titer was nearly equal to 0 in J derived cells while in U251 cells it 
reached 104 pfu/ml even if with an efficiency 100 times lower than in U251EGFRvIII  (Fig. 
4.4.7).  
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Figure 4.4.7 - Viral yield of R-LM613 and R-LM5 in cell expressing EGFRvIII receptors and cell expressing or not HSV-1 
natural receptors. Cell were infected at 1 MOI (pfu/cell) and harvested at 3,24, 48h post infection. Samples were titrated in 
U251EGFRvIII cells. 
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5. Discussion 
 
 
Tumors are still one of the major causes of human mortality. Despite numerous advances made 
for their treatment (surgical resection, chemotherapy, radiotherapy or a combination of these), 
some aggressive types of cancer cannot be treated effectively. Furthermore chemotherapy is very 
invasive as it kills indiscriminately healthy cells and tumor cells, with considerable side effects 
to the patients. 
Oncolytic virotherapy  is a promising therapeutic approach against cancer. Some viruses exert 
cytolytic activity on infected cells in order to ensure a fast and effective viral progeny spread to 
the surrounding tissues. This feature can be exploited to kill tumor cells selectively, sparing 
healthy ones. Furthermore these viruses are able to replicate within cells, unlike drugs that have 
in addition,  a limiting half-life.  
HSV arises as a promising oncolytic vector for several reasons: it has a genome size that can 
accommodate large transgenes (up to 30 kbp) and it is amenable to genetic engineering; it is a 
mild human pathogen against which effective anti virals exist (e.g. acyclovir). Moreover, some 
attenuated oncolytic HSV are already in clinical trials (130, 131).  A side effect related to the 
attenuation strategy is that it affects virus potency. In fact, these viruses are highly safe but 
characterized by lower viral replication, as compared to wt HSV. 
Based on these observations, the objective of this thesis was to construct replication-competent 
recombinant HSV retargeted to tumor specific receptors and simultaneously detargeted from the 
natural HSV-1 receptor, HVEM and Nectin-1. 
 
Three tumor specific receptors were selected for the retargeting approach: HER2, which is over-
expressed in 25-30% of breast and ovarian cancer and glioma multiforme; PSMA, which is over-
expressed in prostate cancer and in neovasculature of solid tumors; and EGFR variant III, which 
is expressed in gliomas. 
The general strategy for retargeting was based on the availability of single chain antibodies 
(scFv) to the target receptors. The scFvs are smaller than the full chain antibodies and offer a 
high binding specificity. The host spectrum of HSV-1 has been modified by the insertion of scFv 
in the envelope glycoprotein gD. Indeed, gD determines the HSV natural tropism by binding to 
HVEM, Nectin-1 and  3-O-sulfate heparan sulfate. Upon binding to the receptor, gD triggers  
fusion by recruiting the glycoproteins gB, gH, and gL. The results of this thesis show the 
successful construction of chimeric forms of gD (gD-scFv) that render HSV-1 able to interact 
only with tumor specific receptors and no longer with the natural receptors. The genetic 
manipulations of viruses were performed using a BAC-HSV-1 genome (162). 
 
o-HSVs retargeted to HER2 receptor  
The HER2 receptor was the first receptor targeted in our studies. This target is clinically relevant 
because of its high expression in breast and ovary tumors, as well as in gliomas. The mAb 
trastuzumab, represented the first HER2-specific therapy available, becomes ineffective within a 
year from the beginning of the therapy, and cannot be used against brain tumors because mAbs 
fail to cross the blood brain barrier (172). 
We have generated three HER2-retargeted viruses: (i) R-LM113 (80), which carries the scFv to 
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HER2 in the deletion of aa 6-38 of gD; (ii) R-LM249, which carries the insertion of scFv in 
place of aa 61-218, which were deleted (80); (iii) R-LM291, a derivative of R-LM249 carrying 
two mutations in gB known to increase the rate of entry of HSV (56); these mutations should  
better the ability of R-LM249 to enter cells (56). 
 
 
R-LM113 was preliminarily characterized in vitro (80). The results of the experiments showed 
that the virus is fully detargeted from the HSV-1 receptors HVEM and Nectin-1, since it is 
unable to grow to titers higher than 103-104 pfu/ml in J-nectin-1, J-HVEM, I-143tk- and Hep2 
cells. Conversely, R-LM113 was able to infect and spread in HER2 positive cells such as J-
HER2 and SK-OV-3. 
The rationale of RLM113 engineering was to locate the scFv to HER2 in a frontal position 
relative to the contact surface between gD and Nectin-1 and eliminate the portion of the protein 
involved in binding to HVEM and Nectin-1. The deletion also encompasses aa 38 later found to 
be important for the binding to Nectin-1 (41). 
The HER2 receptor is expressed in a significant number of high grade gliomas, where it induces 
an increase of anaplasia correlated to a poor prognosis (173). 
In this thesis, the virus has been tested for the safety profile and employed in an in vivo model of 
HER2-expressing gliomas (171, 173).  The murine glioblastoma (GMB) cells were based on the 
over-expression of platelet derived growth factor B (PDGF-B) (171, 174). The experiments were 
conducted in collaboration with Dr. Paolo Malatesta’s group (IST institute of Genoa). 
LM113 showed a high safety profile after intracranial injections,  as compared to wt HSV-1 R-
LM5 in NOD/SCID mice. Animals inoculated with the virus did not show any sign of virus 
spread in the brain, while the wt virus was lethal even at lower doses. The oncolytic activity in 
vivo was evaluated with two different approaches: the virus was administered at the same time as 
tumor cells (early treatment set), or after 45 days following cell inoculation (late treatment set) . 
The treatments with R-LM113 improved the survival time of mice in both experiments. The best 
effect was observed in the early treatment group where mice showed no signs of encephalitis, 
confirming the safety of the virus. The analysis of brains with established tumors (late treatment 
set) in the period immediately following virus administration has shown the ability of R-LM113 
to spread away from the injection site. This result is important in view of clinical application on 
glioma that are a highly invasive and infiltrating tumors. 
This is the first report on the efficacy of a non-attenuated,  replication competent, and retargeted  
o-HSV-1 in a model of intracranial glioblastoma. 
 
 
R-LM249 was designed following the observations by Zhou and Roizman that the gD fragment 
from aa 61 to 218 does not carry out any function required for the virus entry into cells (37). It 
was speculated that this portion of gD, which coincides almost completely with the Ig-folded 
domain, serves as a link between the N-terminal domain and the profusion domain of gD. The 
scFv to HER2 was inserted in place of the Ig-folded domain by means of a two-step replacement 
technique. R-LM249 is at the same time retargeted to HER2 receptor and detargeted from HSV-1 
natural receptors. In fact it was able to infect only HER2 positive cells such as J-HER2, SK-OV-
3, MDA-MB-453 and BT-474, and failed to infect J cells that express no HSV-1 receptor. 
Moreover, the receptor usage was specific since the infection was inhibited only by antibodies 
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against HER2 receptor.  
Although we do not have any direct evidence we assume that the detargeting from both receptors 
is the result of a conformational change in gD due to the size of the insert and the deletion of 
some residues essential to binding to Nectin-1 (e.g. aa 215) and HVEM.  
We were able to grow the virus to 109 pfu/roller bottle and to evaluate the virus oncolytic activity  
in vivo. 
The latter study provided two important results: i) the virus exhibited a high safety profile 
documented by a high LD50 compared to wt HSV-1 ii) R-LM249 was able to inhibit the growth 
of HER2 human tumors cells. The virus was tested  in a subcutaneous ovarian tumor model and 
in a subcutaneous breast tumor model in nude mice. In the ovarian cancer model, a single 
administration resulted in a significant and lasting therapeutic effect (weeks after treatment) in 
HER2-positive tumors up to 0.2 cm3. The repeated injections led to a high percentage of tumor 
free mice up to five months after the last treatment, while the remaining mice showed strongly 
delayed and reduced tumor growth. The most effective dose was 2x107 pfu/mouse. These doses 
are in accordance with those used for other o-HSVs in mice (129). It is unclear why a higher 
dose was less effective. One likely explanation is, the virion aggregates reduced the effect; in 
alternative it caused massive apoptosis of target cells by reducing the reservoir of cells in which 
the virus could replicate and spread. 
 
Glorioso and coworkers recently reported the identification of two mutations in gB 
D285N/A549T, selected by repeated passage of an HSV mutant gD defective in Nectin-1 binding 
(56), which increases the virus’ rate of entry into cells. This discovery was the basis for the 
genetic engineering of R-LM291, that maintains the same backbone of R-LM249 with the 
addition of mutations in gB. So far, the virus has been characterized in cell cultures. R-LM291 
has maintained the retargeting to HER2 receptor and the inability to use HVEM and Nectin-1 as 
receptors for entry. The viral yield shows that there is no substantial increase in the virus 
replication in HER2 positive cells, as compared to R-LM249. The important feature is that the 
virus exhibited an improved cell-to-cell spread in murine cells, as compared to the progenitor R-
LM249. 
 
 
 
o-HSV retargeted to PSMA and EGFRvIII receptors.  
The viruses R-LM593 and R-LM613 are retargeted to PSMA and EGFRvIII receptors, 
respectively. These viruses were generated only in the last year of my thesis, and they have not 
yet been characterized as far as in vivo anti-tumor efficacy is concerned. The rationale for their 
generation is as follows:   
 
Prostate cancer is the leading cause of death in males in the eastern part of the world. In America 
it is the second leading cause of death with 186,000 new cases per year. Effective therapies are 
not available for local and advanced cancer state (148). This tumor is a promising candidate for 
oncolytic virotherapy because the site of the primary tumor is easily accessible to a loco-regional 
virus administration. 
The PSMA receptor is a membrane glycoprotein expressed in highly localized or metastatic 
prostate tumors. It is being employed as a target for imaging-based diagnosis and for the 
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immunotherapy of the tumor (175). In the R-LM593 virus, the anti-PSMA scFv was engineered 
at  the amino terminal portion of gD (delta 6-38). The in vitro characterization showed that the 
retargeting and detargeting have been successfully achieved, since the virus is able to infect only 
cells which express the target receptor, such as J-PSMA and LNCaP. In addition, the cytotoxic 
activity is exerted only towards  PSMA positive cells.  
 
 
Glioblastomas account for approximately 20% of all brain tumors. The disease has a poor 
prognosis in almost all cases because the tumors are resistant to conventional therapies. The 
average survival time from diagnosis is one year. Since these statistics have not changed in the 
last 50 years, glioblastomas are among tumors most suitable to test the efficacy of oncolytic 
HSV. The virus can be inoculated with stereotactic intra-tumoral injections or during surgery. 
The brain compartments affected by the treatment are excluded from the immune system and 
make these tumors suitable to oncolytic virus administration, regardless of the serostatus of the 
patient. 
The EGFRvIII receptor is over-expressed in gliomas and is a mutant form of EGFR. It is 
generated by a deletion of exons from 2 to 7 of wt gene which leads to a deletion of 267 amino 
acids in the extracellular domain of the receptor. Therefore, EGFRvIII is unable to bind ligands 
and is constitutively active (152). The virus R-LM613 was engineered to carry the scFv anti-
EGFRvIII in the N-terminal portion of gD. Infection assays in vivo have shown that the virus is 
able to infect only cells expressing EGFRvIII, such as J-EGFRvIII and U251EGFRvIII, on 
which it exerts a specific cytotoxic activity that is not found in cells expressing the HSV-1 
natural receptors. The yield of R-LM613 confirmed that the virus can replicate only in 
EGFRvIII-expressing cells. 
 
5.1 General considerations and perspectives 
 
A most remarkable aspect of our results is that gD can tolerate dramatic genetic modifications, 
yet viruses carrying such extensively modified forms of gD are viable. My studies show that gD 
can tolerate the deletion of the Ig-folded core and its replacement with a heterologous fragment, 
or the insertion of the scFv at the N-terminus of the molecule; in this case gD had a relatively 
small deletion. Overall, gD can tolerate the insertion of heterologous sequences almost as large 
as the gD ectodomain itself. This extreme plasticity of gD has enabled the construction of a 
number of candidate o-HSVs retargeted to three different cancer-specific receptors.  
In light of the results, we can state that two privileged positions in gD were identified, in which 
an  scFv to tumor-specific receptor can be inserted. The first position is located at the N-terminus 
of gD (deletion from aa 6 to 38); and the second is a replacement of the Ig-folded core of the 
protein (from aa 61 to 218) (44, 80). It is noteworthy that the insertion of scFvs at the two 
positions did not affect the ability of the the scFvs to interact with their cognate receptors, and 
this property was transferred to gD. In turn, gD was still capable (i) of adopting the proper 
conformation, and undergoing structural changes required for the subsequent steps in virus entry. 
Moreover (ii) the retargeted viruses grew to yields just one order of magnitude lower than those 
achieved by viruses carrying wt gD, indicating that overall gD was still capable of carrying out 
its major functions, i.e. receptor recognition, and signaling to downstream virion glycoproteins 
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gH/gL and gB. 
 
The retargeting strategies similar to the ones performed in my studies have been attempted with 
two other enveloped viruses,  measles virus (161, 176) and VSV (177), which have been 
retargeted  towards a number of receptors (CEA, CD20, CD38, PSMA, EGFR, EGFRvIII and 
HER2). These viruses are being tested with promising results in models of intraperitoneal and 
subcutaneous tumors, doubling the survival of treated animals. Probably, the most promising 
results are those obtained with measles virus retargeted to EGFR or EGFRvIII, when applied  in 
an orthotopic xenografts glioma model in immunodeficient mice (178) these viruses caused a 
significant increase of survival time. These examples strengthen the feasibility of the retargeting 
strategy. 
 
Concerning in vivo studies, it remains to determine (i) the oncolytic efficacy of the retargeted 
viruses in models of immunocompetent mice and (ii) a route of administration other to 
intratumoral.  
The immune system could facilitate the clearance of the tumor but on the other side it could also 
decrease virus efficacy. HSV-1 is a common human pathogen and general population carries 
antibody against the virus. Studies in prior HSV-immunized mice demonstrate that immune 
response does not significantly interfere with therapeutic efficacy (179). In a clinical trial phase I 
study the initial intratumoral injection reliably induced a strong anti-HSV immune response in 
HSV seronegative patients, evidenced by increase in antibody titer. However, this does not 
appear to affect the extent of the other clinical responses (130). One of our future objectives will 
be to evaluate the effect of preexisting immunity on the efficacy of our oncolytic HSV redirected 
to HER2. Moreover, we want to test HER2 retargeted viruses in an immunocompetent mouse 
model that leads to the appearance of HER2 positive tumors based on a transgenic mouse 
produced by Genentech. 
So far, our studies have assessed the efficacy of  the loco-regional route of administration. Local 
administration results effective for tumors that can easily be reached through intra-tumoral 
injections or for tissue adjacent to resected tumors. Clearly, the ideal type of administration of o-
HSV is by a systemic route (intraperitoneal for intraperitoneal tumors, or intravenous for 
metastases). 
The currently available HER-2-retargeted o-HSV needs to be optimized in order to be suitable 
for systemic delivery. We plan to introduce the following modifications: HSV glycoproteins gC 
and gB carry heparan sulphate binding sites which mediate virus attachment to a variety of cells, 
including cells negative for HSV receptors. We also plan to delete the heparan sulphate binding 
site, and eventually replace them with scFv to HER-2, so that the final virus will bind with 
increased strength to the target tumor cells.  
 
In conclusion, up to now the studies carried out have shown that i) the o-HSV retargeting is a 
feasible strategy and that ii) viruses retarget to HER2 receptor (R-LM113 and R-LM249) cause a 
target-specific inhibition of  human tumor growth. The use of scFv potentially allows for 
targeting any cellular receptor and the strategy can be applied for retargeted HSV to a wide 
spectrum of receptor families for which a single chain antibody is available. 
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